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If three simple questions and one well chosen laboratory test lead to an unambiguous 
diagnosis, why harry the patient with more? 
Anonymous 
  
DEVELOPMENT OF THE RISK MODEL FOR RESIDENT TRAINING 1 
 
 
 
CHAPTER 1 INTRODUCTION 
Cardiovascular disease is the primary cause of death in the United States (U.S.). 
As the leading cause of cardiovascular morbidity, heart failure is a clinical syndrome with 
an estimated U.S. prevalence of 5.8 million adults and an incidence of 690,000 new cases 
annually. Acute decompensated heart failure (ADHF) accounts for nearly 2 million 
hospitalizations per year, remaining relatively unchanged from 1999 to 2009 in spite of 
new treatment modalities and improved understanding of the heterogeneity of these 
patients. 
Post hospital discharge mortality and readmission rates are unacceptably high, 
reaching 10-20% and 20-30%, within 3 and 6 months (Abraham et al., 2008; Gheorghiade 
& Pang, 2009; Gheorghiade, Vaduganathan, Fonarow, & Bonow, 2013; Lee et al., 2003). 
Hospital readmission is defined as two or more consecutive admissions within a certain 
period of time. The initial hospitalization with the primary discharge of heart failure is 
termed the index hospitalization. The Centers for Medicare and Medicaid Services (CMS) 
requires public reporting of all-cause hospital readmissions within 30 days in patients with 
a primary diagnosis of heart failure at the index hospitalization. According to the Agency 
for Healthcare Research and Quality (n.d.), “Readmission of patients who were recently 
discharged after hospitalization with HF represents an important, expensive and often 
preventable adverse outcome” (para. 3). Readmission within 2, 3 and 6 months are also 
used for measuring clinical outcomes and used in the literature reviewed (Chin, 1997; 
Gheorghiade & Pang, 2009; A.F. Hernandez et al., 2010; Krumholz et al., 2000; Michtalik 
et al., 2011; Philbin & DiSalvo, 1999; Rich et al., 1995; Ross et al., 2009). According to 
the 2008 National Center for Health Statistics (NCHS), heart failure accounts for 35% of 
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cardiovascular disease deaths with nearly 50% of those diagnosed dying within the first 
five years (Bonow et al., 2012; Roger et al., 2012). It is not surprising that hospitalizations 
from to heart failure exceed those due to the total number of all forms of cancer (American 
Heart Association, 2012). 
The economic burden of morbidity and mortality associated with the treatment of 
heart failure must be addressed in light of the spotlight placed on healthcare costs (Dunlay 
et al., 2011; Gheorghiade & Pang, 2009). In response, an increased number of drug trials 
investigating various approaches to treat patients with heart failure were sponsored by 
industry and governmental agencies over the last decade (Ahmed, Aronow, & Fleg, 2006; 
Burger et al., 2002; Felker et al., 2010; Follath et al., 2002; McDonagh et al., 2011; Morris, 
Hatcher, & Reddy, 2006; O'Connor et al., 2011; Publow & Branam; Simpson, Noble, & 
Goa, 2002). However, many of these trials exclude patients with low systolic blood 
pressure either directly, or indirectly. Low systolic blood pressure is often an exclusion 
criterion in drug studies. Indirectly, standard medications used to decrease blood 
pressure may be contraindicated in patients with low systolic blood pressure who are 
alternately treated with exclusionary medications. In addition, standard medications used 
to treat heart failure listed as part of the inclusion criteria are contraindicated in patients 
with low blood pressure. Patients admitted for acute decompensated heart failure with 
low systolic blood pressure have higher mortality rates during hospitalization and post-
discharge than those with normal or high systolic blood pressure (Ambrosy et al., 2013; 
Felker et al., 2010; Franklin & Levy, 2011; Gheorghiade et al., 2012). Associations 
between hypertension and cardiovascular conditions such as heart failure and stroke 
abound in the literature (Psaty, Lumley, Furberg, & et al., 2003; Turnbull, 2003). However, 
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there is paucity of data characterizing the patient with low systolic blood pressure and 
heart failure and thus, this was the basis of this retrospective study conducted at a large 
urban transplant center. 
Exploratory Factor Analysis (EFA) Approach 
Quasi-experimental designed research typically involves advanced statistical 
procedures due to the lack of randomization found in the true experimental design. 
Patients selected for multicentered randomized clinical trials exhibit a different, often 
better, treatment response than those patients who are not enrolled (Badano, 2003; 
Rothwell 2005). Instead of the traditional gold standard randomized clinical trial, 
nonrandomized prospective and retrospective observational studies are becoming a tool 
used to investigate practical outcomes of a treatment in standard clinical practice. Entry 
criteria allow for a broader, less homogenous patient sample than do randomized clinical 
trials. This may improve generalizability of the results. In addition, current evidence-based 
therapies may be continued to allow for the best care of a patient and adherence to the 
Centers for Medicare and Medicaid Services (CMS) reimbursement guidelines. EFA can 
be performed on retrospectively collected data. In EFA, “A factor is a construct, a 
hypothetical entity, a latent variable that is assumed  to underlie tests, scales items, and 
indeed, measure of almost any kind” (Hair, Tatham, Anderson, & Black, 2006, p. 826). 
The resulting factors can then be tested using more expensive experimental 
manipulation. 
Although developed in 1904 by Charles Spearman, the father of modern factor 
analysis is considered Louis L. Thurstone who authored the 1947 classic historical work, 
Multiple Factor Analysis (Hair et al., 2006; Tabachnick & Fidell, 2013; Thurstone, 1931). 
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“Traditionally, factor analysis has been used to explore the possible underlying structure 
in a set of interrelated variables without imposing any preconceived structure on the 
outcome” (Child, 1990, p. 6). EFA is a mathematical technique used for theory 
development or data reduction as depicted in Figures 1 and 4 below (Hair et al., 2006). 
In theory development, EFA can detect the structure in the relationships between 
variables thereby classifying the variables. In data reduction, redundant and irrelevant 
variables are removed (Hair, Anderson, Tatham, & Black, 1992; Tabachnick & Fidell, 
2013). In the heart failure literature reviewed, a variety of statistical approaches including 
multivariate analysis are used to develop risk scores or survival rates (Kannel et al., 1999; 
Sayers et al., 2007; Zugck et al., 2001). However, the use of factor analysis is limited to 
initial psychometric instrument development or assessment of construct validity when 
applied to a specific target group. The Minnesota Living with Heart Failure Questionnaire 
and Kansas City Cardiomyopathy Questionnaire used in research and the inpatient and 
outpatient clinical practice are examples of such instruments (Green, Porter, Bresnahan, 
& Spertus, 2000; Naveiro-Rilo et al., 2010). 
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R= PΦPT + U 
where 
  R = observed data 
  Correlation matrix:      P matrix = factor loading matrix 
                                     PT matrix = transpose of P (transformed matrix) 
                                     Φ matrix = correlation between factors 
                                     U = uniqueness within each variable 
Figure 1. Fundamental Equation of Factor Analysis (Hair et al., 2006) 
 
R′= PΦPT + U 
where  
          R′= reproduced correlation matrix 
Solution for P, Φ, and U where R′ and R differ by a small amount 
Figure 2. Factor Analysis Equation (Hair et al., 2006) 
Statement of the Problem 
The problem addressed in this study was to determine if there are factors that 
characterize patients hospitalized with acute decompensated heart failure with and 
without low systolic blood pressure. Did the use of a variable reduction technique such as 
EFA determine the number of latent constructs in these groups of patients? The choice 
of variables collected were based on those used in the literature reviewed, Framingham 
criteria (see Framingham Heart Study in chapter 2), assessments used for standard 
clinical care at this study site, and others for exploratory evaluation. There were a select 
few variables found in the literature that could not be captured in this retrospective chart 
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abstraction study. Examples are quality of life questionnaires or certain serum laboratory 
results that were either not ordered or are not available. 
American College of Cardiology (ACC) and American Heart Association (AHA) 
guidelines, hospital specific practices and the clinical judgment of the physician are used 
to treat patients with acute decompensated heart who present in the emergency room. 
Many decisions based on commonly collected assessments in the emergency room must 
be made quickly and treatment initiated early. However, many of these therapeutic 
measures are contraindicated in patients whose blood pressure is low at presentation or 
chronically low (Abraham et al., 2008; Buiciuc et al., 2011; Gheorghiade et al., 2006; Miller 
& Skouri, 2009). These patients are considered sicker and are treated with drugs such as 
intravenously administered inotropes to improve cardiac output. Yet these same drugs 
are associated with increased morbidity and mortality. In addition, invasive monitoring is 
more common in these patients. Database analysis of several heart failure registries 
support improved outcomes when treatment is initiated early upon presentation in the 
emergency room (Abraham et al., 2008; Mebazaa et al., 2008; Subbe, Kruger, 
Rutherford, & Gemmel, 2001). Thus a quick risk stratification system to score patients 
presenting with acute decompensated heart failure has the potential to lead to effective 
individualized treatment modalities. 
Purpose of the Study 
The purpose of this study was to characterize patients hospitalized with acute 
decompensated heart failure with and without low systolic blood pressure using EFA. 
Patients requiring hospitalization due to acute decompensated heart failure present with 
distinct clinical characteristics including severe symptoms that necessitate rapid 
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treatment that cannot be delivered in an outpatient setting. Response to treatments 
varies, and those requiring invasive diagnostic procedures, coronary interventions or 
surgical treatments meet the guidelines for admission. Each patient presents with clinical 
signs and symptoms, a heart failure history, and comorbidities. Direct and surrogate 
measurements are then measured. Safety and cost-effective management is paramount, 
but there is a deluge of clinical data. The question investigated was could the method of 
data reduction using EFA elicit a parsimonious group of factors to summarize the 
relationship between these variables? 
A better understanding of the characteristics and outcomes of patients presented 
with acute decompensated heart failure with and without low systolic blood pressure could 
potentially lead to individualized treatment modalities tailored to effectively and 
economically improve care. 
Research Questions 
1. What were the common factors in patients with acute decompensated heart 
failure? 
2. What were the common factors in patients with acute decompensated heart failure 
and normal or high systolic blood pressure? 
3. What were the common factors in patients with acute decompensated heart failure 
and low systolic blood pressure? 
4. Was there a difference in the common factors in patients with and without low 
systolic blood pressure and acute decompensate heart failure? 
Operational Definitions (add as needed, definitions of signs and symptoms or other 
technical terms will be summarized in the appendices) 
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Acute decompensated heart failure: Acute heart failure syndrome is defined as 
gradual or rapid change in heart failure (HF) signs and symptoms resulting in a need for 
urgent therapy. Acute heart failure syndromes encompasses at least 3 clinical distinct 
entities: (1) Worsening chronic HF associated with reduced or preserved LVEF (70% of 
all admissions); (2) de novo HF (e.g., after a large MI; sudden increase in blood pressure 
superimposed on a noncompliant LV) (25% of all admissions); and (3) advanced HF (i.e., 
refractory to therapy) with severe LV systolic dysfunction, associated with a continually 
worsening low-output state (5% of all admissions) (Gheorghiade et al., 2005, pp. 3594-
3959). 
Blood pressure:  pressure exerted by the blood upon the walls of the blood vessels 
and especially arteries, usually measured on the radial artery by means of a 
sphygmomanometer, and expressed in millimeters of mercury either as a fraction having 
as numerator the maximum pressure that follows systole of the left ventricle of the heart 
and as denominator the minimum pressure that accompanies cardiac diastole or as a 
whole number representing the first value only a blood pressure of 120/80—abbreviation 
BP. Diastolic blood pressure is the lowest arterial blood pressure of a cardiac cycle 
occurring during diastole of the heart and systolic blood pressure is the highest arterial 
blood pressure of a cardiac cycle occurring immediately after systole of the left ventricle 
of the heart (Merriam-Webster, n.d.). 
Heart failure:  Heart failure is a syndrome caused by cardiac dysfunction, generally 
resulting from myocardial muscle dysfunction or loss and characterized by left ventricular 
dilation or hypertrophy [or both]. Whether the dysfunction is primarily systolic or diastolic 
or mixed, it leads to neurohormonal and circulatory abnormalities, usually resulting in 
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characteristic symptoms such as fluid retention, shortness of breath, and fatigue, 
especially on exertion. In the absence of appropriate therapeutic intervention, heart failure 
is usually progressive at the level of both cardiac function and clinical symptoms. The 
severity of clinical symptoms may vary substantially during the course of the disease 
process and may not correlate with changes in underlying cardiac function. Although 
heart failure is progressive and often fatal, patients can be stabilized and myocardial 
dysfunction and remodeling may improve, either spontaneously or as a consequence of 
therapy. In physiologic terms, heart failure is a syndrome characterized by elevated 
cardiac filling pressure or inadequate peripheral oxygen delivery, at rest or during stress, 
caused by cardiac dysfunction (Lindenfeld & Arnold, 2006, p. e10). 
Heart failure with preserved ejection fraction:  Also referred to as heart failure with 
a nondilated left ventricle.  A clinical syndrome characterized by signs and symptoms of 
heart failure with preserved left ventricular ejection fraction. Most commonly associated 
with a nondilated left ventricular chamber. May be the results of valvular disease or other 
causes (Lindenfeld & Arnold, 2006, p. e10). 
Heart failure with reduced ejection fraction:  Also referred to as heart failure with a 
dilated left ventricle. A clinical syndrome characterized by signs and symptoms of heart 
failure and reduced left ventricular ejection fraction. Most commonly associated with left 
ventricular chamber dilation (Lindenfeld & Arnold, 2006, p. e10). 
International Classification of Diseases, Ninth Revision, Clinical Modification code 
(ICD-9) - code and classify morbidity data from the inpatient and outpatient records, 
physician offices, and most National Center for Health Statistics (NCHS) surveys (n.d., 
para 3). 
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Statistical Definitions 
The following statistical definitions were taken from Hair et al. (1992, p. 224). 
Common factor analysis:  A factor model in which the factors are based upon a 
reduced correlation matrix.  That is, communalities…are inserted in the diagonal of the 
correlation matrix, and the extracted factors are based only on the common variance, with 
specific and error variance excluded. 
Correlation matrix:  A table showing the intercorrelations among all variables. 
Eigenvalue:  The column sum of squares for a factor; also referred to as the latent 
root.  It represents the amount of variance accounted for by a factor 
Factor:  A linear combination of the original variables.  Factors also represent the 
underlying dimensions (constructs) that summarize or account of the original set of 
observed variables 
Factor loadings:  The correlation between the original variables and the factors, 
and the key to understanding the nature of a particular factor. Squared factor loadings 
indicate what percentage of the variance in an original variable is explained by a factor. 
Factor matrix:  A table displacing the factor loadings of all variables on each factor. 
Factor score:  Factor analysis reduces the original set of variables to a new smaller 
set of variables, or factors.  When this new smaller set of variables (factors) is used in 
subsequent analysis (e.g., discriminant analysis), some measure or score must be 
included to represent the newly derived variables. This measure (score) is a composite 
of all of the original variables that were important in making the new factor.  The composite 
measure is referred to as a factor score. 
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Orthogonal:  Refers to the mathematical independent of factor axes to each other 
(i.e., at right angles, or 90 degrees). 
Orthogonal factor solutions:  A factor solution in which the factors are extracted so 
that the factor axes are maintained at 90 degrees. Thus each factor is independent of, or 
orthogonal from, all other factors. The correlation between factors is arbitrarily determined 
to be zero. 
Trace:  The sum of the squares of the numbers on the diagonal of the correlation 
matrix used in the factor analysis. It represents the total amount of variance on which the 
factor solution is based…With common factor analysis, the trace is equal to the sum of 
the communalities on the diagonal of he reduced correlation matrix (also equal to the 
amount of common variance of the variables being analyzed). 
Limitations 
The nature of limitations in this study included data selection and collection, the 
timing of the study and the statistical approach chosen. 
The data for this retrospective chart review of a convenience sample of patients 
was limited to the available variables collected as part of standard clinical care at one 
large urban transplant center. Patient characteristics such as socioeconomic status, 
ethnicity, and healthcare coverage, or even the level of care provided by the hospital 
(primary versus secondary versus tertiary) may differ in other centers. Thus, the 
generalizability, or external validity of the results in this sample of patients was limited. 
Alternatively, unintentional bias was reduced and clinical equipoise did not exist since the 
treatment had already occurred. 
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This study was performed on patient encounters prior to the Patient Protection and 
Affordable Care Act of 2010 (PPACA) which heralds a more reliable, accessible 
healthcare system offering higher quality and higher value care (Rak & Coffin, 2013). 
Information-sharing via electronic medical records and access to primary care may 
directly affect standard clinical practice. Thus the patient seen in the emergency room at 
the time of this study may look very different in the future. The generalizability of the study 
results to these potential changes in care is beyond the scope of this paper. 
Lastly, but most importantly are the limitations of the EFA method for data 
reduction and the technical difficulty that may be experienced by novices such as the 
writer of this dissertation. Data reduction using EFA is a highly pragmatic function. 
Computer software programs such as SPSS® and SAS® allow for quick and easy 
computations and a large number of variables can be directly imported from databases 
such as Excel®. However, EFA is a complex procedure with fewer absolute guidelines or 
rules for selecting options compared to other statistical approaches. The steps taken were 
detailed, justified by the literature reviewed and alternate choices were discussed. The 
seven stages in factor analysis design as outlined by Hair et al. (2006) were employed in 
this analysis. 
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CHAPTER 2 REVIEW OF THE LITERATURE 
The burden of heart failure on everyday living places a physical toll on patients, 
and increasingly so, when worsening symptoms result in hospitalizations placing them at 
a particularly high risk for adverse outcomes after discharge (Heidenreich et al., 2013). 
Between fifteen to twenty percent of patients present with low systolic blood pressure, 
with or without signs or symptoms of hypoperfusion (Buiciuc et al., 2011; Saito et al., 
2010). Low blood pressure often precludes the use of drugs used to treat low cardiac 
output but could the causes of hypotension differ in this group (Gheorghiade et al., 2012)? 
“Management of AHFS is challenging given the heterogeneity of the patient population, 
absence of a universally accepted definition, incomplete understanding of its 
pathophysiology, and lack of robust evidence-based guidelines” (Gheorghiade & Pang, 
2009, p. 557). The aim of this study was to use EFA for data reduction to elicit a 
parsimonious set of factors summarizing the relationships between variables by 
measuring intercorrelations of the clinical variables collected as part of standard care, 
and abstracted from electronic medical records. 
A comprehensive review of the literature presented includes a discussion of heart 
failure, the Framingham Heart Study and the Heart Failure Classification System. The 
purpose of integrating clinical trial results and best clinical practices to produce 
evidenced-based guidelines opens the discussion of past drug development for heart 
failure. 
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Heart Failure 
Heart failure is commonly defined as a pathophysiological state causing abnormal 
cardiac function resulting in a weakened heart that fails to adequately pump blood at a 
rate required by peripheral tissues and organs. Although only the right or left side may be 
affected, often both sides of the heart are involved. Chatterjee and Massie (2007) 
discussed the definition of heart failure stating, “confusions and controversies regarding 
the definitions, pathophysiology, prognosis and management of DHF and SHF continue” 
(p. 569). Heart failure is generally long term or chronic but may also have a sudden onset. 
Determining the underlying cause of heart failure in such a heterogeneous group has 
prognostic and therapeutic importance. Genetic, hormonal, and dietary factors play an 
important role in heart failure (Mosterd & Hoes, 2007; Yancy et al., 2013). 
As indicated by the American College of Cardiology Foundation/American Heart 
Association Task Force on Practice Guidelines of 2009, “Heart failure is a complex clinical 
syndrome that can result from any structural or functional cardiac disorder that impairs 
the ability of the ventricle to fill with or eject blood” (Hunt et al., 2009, p. e397). Thus by 
definition, heart failure has many causes and certain risk factors as listed in Table 1. 
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Table 1 
Causes and Risks of Heart Failure 
 
Adapted from Mann (2011) 
Management of acute decompensated heart failure differs than that of chronic 
compensated heart failure. Common factors that precipitate acute decompensated heart 
failure as listed in Table 2 include factors attributed to the onset of heart failure, such as 
acute myocardial ischemia, hypertension and excessive alcohol or cocaine use (Murphy 
& Llyod, 2007; Yancy et al., 2013). The goal to optimize volume status and relieve the 
Most Common  Left-sided heart failure include
·   ST-segment elevation myocardial infarction ·   Ischemic heart disease
·   Untreated or inadequately treated hypertension ·   Hypertension
Rare ·   Arrhythmias (especially atrial fibrillation)
·   Uncommon high-output states (osteitis 
…deformans , beriberi)
·   Valvular disease (aortic stenosis , aortic 
....regurgitation , mitral regurgitation)
·   Valvular disease (tricuspid 
....incompetence, pulmonary stenosis) ·   Cardiomyopathy
·   Infective endocarditis ·    High-output states (anemia, hyperthyroidism)
·   Isolated right ventricular cardiomyopathy ·   Congenital heart disease
·   Hyperthyroidism ·    Volume overload (e.g., renal failure /dialysis)
·   Vitamin deficiency ·    Alcoholism
·   Myocarditis Right-sided heart failure
·   Toxic substances ·         Left-sided heart failure (most common)
·   Illicit drugs (e.g., cocaine and amphetamines) ·         Chronic pulmonary disease
·   Endomyocardial fibrosis ·         Pulmonary embolism
·   Hemochromatosis ·         Primary pulmonary hypertension
·   Amyloidosis ·         Valvular disease (mitral stenosis)
·         Obesity ·         Diabetes
·         Obstructive sleep apnea·         Physical inactivity
·         Cigarette smoking·         Renal insufficiency
·         Infection, especially pulmonary infection
                                                                                                                                  Risk factors        
° Obesity ° Diabetes
° Obstructive Sleep Apnea ° Physical Inactivity
° Cigarette Smoking ° Renal Insufficiency
° Infection, especially pulmonary infection
Risk Factors
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signs and symptoms of acute decompensated heart failure in patients with chronic heart 
failure can be achieved by quantitative evaluation of hemodynamics indices and/or clinical 
assessments. In acute decompensated heart failure, the therapeutic approach depends 
on whether there is evidence of volume overload, low cardiac output or indicators of both. 
Invasive hemodynamic monitoring or signs and symptoms are used to classify patients in 
one of four Forrester Hemodynamic subsets (Forrester, Diamond, Chatterjee, & Swan, 
1976). A pulmonary artery catheter is advanced through a large vein to the right side of 
the heart and into a small branch of the pulmonary artery during a right heart 
catheterization in complex patients who require intensive hemodynamic monitoring. 
However, most patients are classified based on the signs and symptoms exhibited at 
presentation. 
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Table 2 
Common Factors that Precipitate Acute Decompensated Heart Failure 
 
Adapted from the 2013 American College of Cardiology Foundation and American 
Heart Association Practice Guidelines (Yancy et al., 2013, p. e285) 
The 2013 American College of Cardiology Foundation and American Heart 
Association practice guides for the management of patients with acute decompensated 
heart failure and fluid overload include the following; 
 intravenous diuretic treatment 
 patients receiving loop diuretic therapy should receive an initial parenteral dose 
greater than or equal to their chronic oral daily dose; then dose should be serially 
adjusted 
 heart failure with reduced ejection patients on guideline-directed medical therapy 
should continue this therapy  except in cases of hemodynamic instability or where 
contraindicated 
● Nonadherence with medication regimen, sodium and/or fluid restriction
● Acute myocardial ischemia
● Uncorrected high blood pressure
● Atrial Fibrillation and other arrhythmias
●
Recent addition of negative inotropic drugs (e.g., verapamil, nifedipine, 
diltiazem, beta blockers)
● Pulmonary embolus
●
Initiation of drugs that increase salt retention (e.g., steroids, 
thiazolidinediones, NSAIDs)
● Excessive alcohol or illicit drug use
●
Endocrine abnormalities (e.g., diabetes mellitus, hyper- or 
hypothyroidism)
● Concurrent infections (e.g., pneumonia, viral illnesses)
●
Additional acute cardiovascular disorders (.e.g, valve disease 
endocarditis, myopericarditis, aortic dissection)
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 initiation of beta-blocker therapy at a low dose is recommended after optimization 
of volume status and discontinuation of intravenous agents 
 thrombosis/thromboembolism prophylaxis is recommended 
 Serum electrolytes, urea nitrogen, and creatinine should be measured during 
titration of heart failure medications, including diuretics 
 when diuresis is inadequate, it is reasonable to 
 give higher doses of intravenous loop diuretics 
 add a second diuretic 
 low-dose dopamine infusion may be considered with loop diuretics to improve 
diuresis 
 ultrafiltration may be considered for patients with obvious volume overload 
 ultrafiltration may be considered for patients with refractory congestion 
 intravenous nitroglycerin, nitroprusside, or nesiritide may be considered an 
adjuvant to diuretic therapy for stable patients 
 patients with volume overload and severe hyponatremia, vasopressin antagonists 
may be considered. (Yancy et al., 2013) 
Independent predictors of mortality in patients admitted to hospital with 
decompensated heart failure include age (per year), male gender, diabetes, renal 
dysfunction, ankle edema, weight, low blood pressure (defined as systolic pressure <110 
mm Hg or diastolic <70 mmHg) and no use of beta blockers were reported by Mosterd 
and Hoes (2007). “In outpatients with chronic HF, a hospitalization is one of the strongest 
prognostic predictors for increased mortality” was concluded by Gheorghiade et al. (2013, 
p. 391). Abraham et al. (2008) analyzed registry data from 259 hospitals determining the 
risk of in-hospital mortality increased in patients who are older, exhibit a low systolic blood 
pressure, low sodium level, elevated heart rate, or high serum creatinine level at 
admission. Fonarow, Adams, Abraham, Yancy, and Boscardin (2005) identified variables 
such as vital signs, and laboratory data as low, intermediate, and high predictors of 
mortality in hospitalized patients. A low admission systolic blood pressure of <115 mm Hg 
was determined the second best predictor of mortality. 
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Classification of Patients with Acute Decompensated Heart Failure 
Cardiac output is the volume of blood that the heart pumps or ejects each minute 
in liters per minute. Cardiac output is dependent upon preload and afterload. Patients with 
heart failure have a flatter Frank-Starling curve due to impaired ventricular performance 
requiring higher filling pressure to produce stretch to maintain output. Preload is 
measured by the pulmonary capillary wedge pressure. A value greater than 18 mmHg 
indicates volume overload, congestion or wet, whereas a value less than 18 mmHg 
indicates the patient is dry (Joseph, Cedars, Ewald, Geltman, & Mann, 2009). Signs and 
symptoms when a patient is wet include dyspnea, cough, paroxysmal nocturnal dyspnea, 
pulmonary congestion on chest x-ray, peripheral edema, ascites, hepatomegaly, 
splenomegaly and jugular vein distention. Afterload measured by systolic vascular 
resistance indicates adequate perfusion to the peripheral tissues. Higher than normal 
systolic vascular resistance  indicates systemic vasoconstriction resulting in a cold state 
(Joseph et al., 2009). Noninvasive blood pressure readings may be used as surrogates 
for afterload. 
Cardiac index is a measure of cardiac output that has been normalized for body 
size based body surface area. A cardiac index greater than 2.2 L/min/m2, lower than the 
normal range of 2. 8-4. 2 L/min/m2, indicates adequate perfusion in patients with heart 
failure (Joseph et al., 2009; Nohria et al., 2003). The term warm is used for cardiac indices 
greater than 2.2 L/min/m2 and the term cold for lower values indicates poor perfusion of 
blood to the body’s tissues (Nohria et al., 2003). Signs and symptoms of poor tissue 
perfusion are cold clammy extremities, fatigue, altered mental status and low blood 
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pressure and indicative of poor end organ perfusion are abnormal liver enzymes or serum 
creatinine. 
Thus cardiac output can be assessed hemodynamically or clinically as warm and 
dry, warm and wet, cold and dry, and cold and wet, and the appropriate therapy can be 
applied (refer to Figure 3). These measures include optimizing chronic oral therapy, use 
of diuretics, vasodilators or inotropes, and/or gentle fluid hydration. Unfortunately, 
patients with low systolic blood pressure, as often seen in the cold and dry subset, may 
not be treated with vasodilators, or caution with diuretic use may be needed in the two 
wet subsets. Even optimization of chronic oral therapy in the warm and dry subset may 
be difficult as beta blockers and angiotensin-converting enzyme inhibitors lower blood 
pressure. 
 
Figure 3. Classification of patients presenting with acutely decompensated heart 
failure. Adapted from Joseph et al. (2009) and Nohria et al. (2003) 
Framingham Heart Study 
President Franklin D. Roosevelt’s death from hypertensive heart disease and 
stroke in 1945 prompted the Framingham Heart Study (McKee, Castelli, McNamara, & 
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Kannel, 1971). The Framingham Heart Study followed an original cohort and two 
subsequent generations to identify genetic and environmental factors influencing the 
development of cardiovascular and other diseases. As a result, the current understanding 
in the epidemiology, pathophysiology, diagnosis, treatment and seminal findings of the 
risk factors of cardiovascular disease has improved globally (Kannel et al., 1999; McKee 
et al., 1971). The Framingham Heart Failure Diagnostic Criteria applied to both acute and 
chronic heart failure are as follows in Table 3:  
DEVELOPMENT OF THE RISK MODEL FOR RESIDENT TRAINING 22 
 
 
 
Table 3 
Framingham Decompensated Heart Failure Criteria 
 
A definite diagnosis of congestive heart failure requires that a minimum of two 
major or one major and two minor criteria be present concurrently. The 
presence of other conditions capable of producing the symptoms and signs 
are considered in evaluating the findings. 
Adapted from: Framingham Heart Study (2006, p. 6) 
An expert consensus document defining acute heart failure resulted from the first 
and second International Workshop on Acute Heart Failure Syndrome held in May of 2004 
and April of 2005. According to this seminal paper by Gheorghiade and colleagues 
(2005), 
AHFS is defined as gradual or rapid change in heart failure (HF) signs and 
symptoms resulting in a need for urgent therapy. These symptoms are 
1
Paroxysmal nocturnal dyspnea or 
orthopnea
1 Bilateral ankle edema
2
Distended neck veins (in other 
than the supine position)
2 Night cough
3 Rales 3 Dyspnea on ordinary exertion
4 Increasing heart size by x-ray 4 Hepatomegaly
5
Acute pulmonary edema on chest 
x-ray
5 Pleural effusion by x-ray
6 Ventricular S(3) gallop 6
Decrease in vital capacity by 
one-third from maximum 
record
7
Increased venous                                                 
pressure >16 cm H20
7
Tachycardia (10 beats per 
minute or more)
8 Hepatojugular reflux 8
Pulmonary vascular 
engorgement on chest x-ray
9
Pulmonary edema, visceral 
congestion, cardiomegaly shown 
on autopsy
10
Weight loss on CHF treatment of 
10 lbs/5days
Major Criteria Minor criteria
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primarily the result of severe pulmonary congestion due to elevated left 
ventricular (LV) filling pressures (with or without low cardiac output). (p. 1) 
Today, acute decompensated heart failure is defined by a disorder associated with 
sodium and water retention, left ventricular dysfunction of the heart, and neurohormonal 
activation. 
Heart Failure Classification System 
Heart failure is a progressive disorder that can be represented as a clinical 
continuum. Stratiﬁcation of the severity of heart failure is key to therapeutic management 
and long-term prognosis. In 1928, the first version of the New York Heart Association 
(NYHA) classification system was used to classify heart failure based on functional 
limitations and symptomatic status depending on the degree of effort due to fatigue or 
dyspnea (Appendix A). Capable of readily shifting with emergency treatment such as 
diuresis, or with the addition of a guideline recommended therapy over time, the functional 
class of a given patient is not always static. The American College of Cardiology 
Foundation (ACCF) and the American Heart Association (AHA) stages are used to 
determine risk for developing the disease, disease severity and prognosis (Hunt et al., 
2001). Staging includes both asymptomatic and symptomatic phases in the development 
of heart failure (Hunt et al., 2001). Patients without structural heart disease or symptoms 
of heart failure with other comorbidities such as diabetes, hypertension, atherosclerotic 
vascular disease, metabolic disease, obesity or  cardiotoxin exposures such as (i.e., due 
to chronic alcoholism, cocaine use, chemotherapy, radiotherapy, or certain medications) 
are at high risk for heart failure and classified as Stage A. Stage B includes those patients 
with previous myocardial ischemia, asymptomatic valvular heart disease and left 
ventricular remodeling of the heart. Patients with symptoms of heart failure with either 
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reduced left ventricular ejection fraction (typically 40% or less), borderline preserved (41-
49%) or preserved (50% or greater), are Stage C even if they later become asymptomatic. 
Those with marked heart failure symptoms at rest and multiple hospital readmissions are 
Stage D. However, patients may skip a stage, or revert to an earlier stage when 
treatments result in reverse remodeling. The functional rating scale for left ventricular 
ejection fraction measured by echocardiography is depicted in Table 4. 
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Table 4 
Left Ventricular Ejection Fraction as Measured by Echocardiogram 
 
Adapted from(Ashley & Niebauer, 2004) 
Many clinical trials are designed using NYHA class as an entry criterion, or as the 
basis for analyzing interactions and outcomes (Ahmed et al., 2006; Bouvy, Heerdink, 
Leufkens, & Hoes, 2003; Kubo et al., 2004; Sakurai et al., 2003; Soejima et al., 2000). 
Concordance between NYHA classification, ACCF/AHA staging and/or other objective 
measures such as left ventricular ejection fraction measured in diagnostic imaging 
studies, functional exercise testing using the six minute walk test (6MWT), serum analysis 
measuring brain natriuretic peptide levels (BNP) and symptoms such as dyspnea are 
extensively studied (Beatty, Schiller, & Whooley, 2012; Carvalho, Garrod, Bocchi, Pitta, 
& Guimaraes, 2010; Rostagno et al., 2003; Wieczorek et al., 2002). Raphael et al. (2007) 
studied the use of NYHA classification using three methods. A Medline review of clinical 
trials often did not explain the criteria used to determine NYHA class. Peak oxygen 
consumption as measured during cardiopulmonary testing did not correlate to a patient’s 
self-reported walking distance. Their interoperator study using class II and class III 
Ejection Fraction Functional Rating Heart Failure Spectrum
45%–70% Normal
Heart failure with preserved 
ejection fraction
35%–45% Mild impairment
Heart failure with reduced 
ejection fraction
25%–35% Moderate impairment
Heart failure with reduced 
ejection fraction
<25% Severe impairment
Heart failure with reduced 
ejection fraction
<15%
End-stage/transplant 
candidates
Heart failure with reduced 
ejection fraction
5%
Is compatible with life but not 
long life
Heart failure with reduced 
ejection fraction
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patients also failed to show reliability. Thus, they concluded, “No consistent method of 
assessing NYHA class is in use and the interoperator study on class II and class III 
patients gave a result little better than chance” (p. 2). Another functional test, the six 
minute walk test (6MWT), was found to be predicted by NYHA class (Athilingam, D’aoust, 
Zambroski, McMillan, & Sahebzemani, 2013). However, cardiac structural abnormalities 
defined by the ACC/AHA staging system did not exhibit any correlation to the six minute 
walk test. As well, there was no concurrent validity between NHYA class and ACC/AHA 
Stages of heart failure. 
Is there a legitimate reason to use either NHYA class or ACC/AHA stages in clinical 
trial design? Gary G. Koch, biostatistics professor and director of the Biometrics 
Consulting Laboratory at the University of North Carolina at Chapel Hill is a noted expert 
in categorical data analysis especially in medical research. According to Koch (as cited 
in Dmitrienko, Molenberghs, Chuang-Stein, & Offen, 2005), “randomization- and model-
based methods have been historically motivated by two different sampling schemes. As 
a result, randomization-based inferences are generally restricted to a particular study, 
whereas model-based inferences can be generalized to a larger population of patients” 
(p. 2). If NHYA class or ACC/AHA staging are valid and reliable functional or structural 
measures of heart failure, respectively, then each model can be used to test diagnostic 
and prognostic markers. 
Evidence-Based Guidelines 
Coined by Dr. Gordon Guyatt in 1990 at McMaster University, evidence- based 
medicine combines clinical expertise with scientifically sound research (Guyatt et al., 
1992). Research in the form of clinical trials and other findings aim to provide evidence 
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whether or not a new treatment is safe and more effective compared to current 
treatments. The foundation of evidence-based medicine is the evidence itself, which must 
be gathered and collated from a systematic review of relevant individual published 
research studies. Traditional narrative reviews and expert commentaries previously used 
to summarize research evidence are replaced by systemic reviews of the best available 
research. The Evidence Hierarchy places systemic reviews of randomized controlled 
trials at the highest level notated by Level 1a with expert opinion at the lowest level 
notated by Level 5 (Yancy et al., 2013). 
A systematic review is a summary of the critical appraisal of clinical literature used 
to answer a focused clinical question without bias using a predetermined, organized 
methodology. The methodology includes pre-specified eligibility criteria and a systematic 
search strategy to identify relevant comparable (homogenous) high quality studies. Unlike 
traditional reviews, the evidence from each study is systematically summarized. In a 
literature review, the evidence is summarized using a qualitative approach to provide a 
summary of the targeted topic, not a specific question. 
The term meta-analysis is an unbiased summary of all of the highest quality 
information from several studies using set rules or standards in a systematic review that 
is statistically analyzed to provide a combined estimate. Over the past 20 years, the 
Cochrane Collaboration electronically publishes review from the medical literature in the 
Cochrane Database of Systemic Reviews. “This is an international organization whose 
goal is to help scientists, physicians, and decision makers make well-informed decisions 
about health care by coordinating systematic reviews of the effects of health care 
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intervention” (Jadad & Haynes, 1998, p. 2). Systematic reviews and meta-analyses are 
key elements of evidence-based healthcare. 
Management of heart failure ought to be guided by evidence-based guideline 
directed diagnosis, evaluation and treatment. Evidence from clinical trials often guides 
selection of therapy in the clinical setting. Judicious care should be taken when treatment 
outcomes from clinical trials are extrapolated to patients in the clinical setting whose 
characteristics differ than those enrolled in clinical trials. 
Although race is a poor marker of variation, the combination of isosorbide dinitrate 
and hydralazine exhibits efficacy in the treatment of African Americans with heart failure 
reducing mortality by 43% (Golwala et al., 2013; Hammermeister et al., 2009; Sharma, 
Colvin-Adams, & Yancy, 2014). However, the association between the use of non-
potassium-sparing diuretics for fluid management and increased mortality and 
rehospitalization is less understood (Brandimarte et al., 2010; Golwala et al., 2013). One 
reason that accounts for this inability to draw conclusions is that patients entered in clinical 
trials must meet strict entry criteria to optimize the likelihood of measuring efficacy and 
safety of the treatment with positive outcomes that are acceptable to approval agencies 
such as the Food and Drug Administration (FDA), Health Canada or European Medicines 
Agency. Entry criteria include several inclusionary and exclusionary criterions that limit 
the heterogeneity of patients and decrease the potential risks of the treatment. To improve 
the characteristics of the study population, the identification of novel biomarkers and 
surrogate endpoints is needed (Fonarow et al., 2007; Gheorghiade & Rushchitzka, 2011). 
Patients selected from the target population may not reflect the characteristics of those in 
the general heart failure population. Thus, the key goal is to select patients reflective of 
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the heart failure condition, yet homogenous enough to reveal the effect of the treatment 
rather than differences between individual patients in the study. 
In part due to ethical considerations, most studies require patients to be medically 
stable for at least a few months prior to study entry and to likely be stable for duration of 
the study. Less stable patients are usually offered standard therapy of FDA approved 
drugs whether or not their effectiveness has been shown in clinical trials (Morris et al., 
2006). Medical stability is defined by the type of study and mechanism of action of the 
drug. A patient who is medically stable on a standard heart failure therapy may be the 
ideal candidate to measure the superiority of a new drug compared to its FDA approved 
Counterpart. In this case, entry criteria may define medical stability as no change in 
cardiovascular drug(s) class or significant dose adjustment up to six months of study 
entry, no hospitalization within the past twelve months, and no new treatment plan that 
may affect heart failure. At the other end of the spectrum, medical stability may be defined 
as stability other than the acute decompensation of heart failure that resulted in the 
hospitalization. However, regardless of the definition of medical stability, patients with a 
chronically low systolic blood pressure are often excluded in study participation. 
Another issue seen is when patients meet entry criteria but decline to enroll, or are 
deemed inappropriate by the clinical investigator or sponsor for various reasons raising 
questions about the applicability of the study results to the greater population (Kaptchuk, 
2001; Rothwell, 2005). In a commentary published in a peer reviewed journal, Professor 
Ted J. Kaptchuk addressed the potential bias of the gold standard placebo controlled 
randomized clinical trial by stating, “It seems that the most ‘rigorous’ evidence may 
produce deviations from the truth” (2001, p. 546). Patients who are asked to stop excluded 
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drugs or therapies may decline to participate. Patients deemed compliant with a drug 
requiring once a day dosing may not be compliant with more than once a day dosing. And 
most applicable to the current study, although not an exclusion criterion, the clinical 
investigator may deem a patient low systolic blood pressure ineligible, in part due to the 
potential risk of a significant drop in blood pressure. The negative effect is twofold: an 
increase in serious adverse events and removing the patient from the study treatment 
and/or the study. In an intent-to-treat study, this could have a deleterious effect on study 
outcomes, especially if the patient was randomized to the active group (active study drug 
or treatment). Underrepresentation of patients with borderline or low systolic blood 
pressure in heart failure clinical trials makes it difficult to understand the full impact of 
medical interventions and the generalizability or external validity of the use of such 
interventions. 
Past drug development for heart failure. Over the past 20 years, chronic heart 
failure was the primary focus of clinical and epidemiological research with only a few 
studies targeting patients hospitalized with acute decompensated heart failure (Adams et 
al., 2005; Amin, 2008; Badano et al., 2004; Smith et al., 2004; Tavazzi et al., 2006). Most 
of the heart failure research has focused on developing new drugs for FDA approval, or 
testing approved drugs in the initial hours of presentation in the emergency room (Felker 
et al., 2010). An example of the latter is the much studied drug nesiritide, approved in 
2001 by the FDA for use as a first line treatment in the emergency room for dyspnea in 
acute decompensated heart failure. In a 2005 meta-analysis of trials, nesiritide was 
associated with short-term risk of mortality when used to treat acute decompensated 
heart failure. Prompted by such a strong signal of risk, five years later the Acute Study of 
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Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF), a 
multicenter randomized trial with over 7,000 patients demonstrated an acceptable safety 
profile but no apparent efficacy (O'Connor et al., 2011; Sackner-Bernstein, Kowalski, Fox, 
& Aaronson, 2005). Registries were created based on these clinical trials and volumes of 
clinical data were collected. Although the evidence for nesiritide’s clinical efficacy may not 
be robust, expert opinions based on retrospective chart reviews or anecdotal information 
guide the decision to treat or not to treat with nesiritide.  
The controversy of nesiritide’s efficacy continues to this day (Felker et al., 2010; 
A. F. Hernandez et al., 2009; McDonagh et al., 2011; O'Connor et al., 2011; Sackner-
Bernstein et al., 2005; Wang et al., 2004; Yan et al., 2014). Even so, nesiritide and other 
natriuretic peptide drugs continue to be trialed for acute decompensated heart failure. 
However, due to its hypotensive properties, patients with low systolic blood pressure are 
excluded from study participation. The result is that one of the most intensively studied 
drug, nesiritide, where volumes of clinical data were used to paint the clinical picture of a 
patient with acute decompensated heart failure, excludes patients with low systolic blood 
pressure. This is reminiscent of the days when the majority of drugs were tested on white 
males spurring such action as the National Institutes of Health (NIH) Revitalization Act of 
1993 (PL103-43) requiring inclusion of women and minorities as participants in NIH-
funded clinical trials (Swanson & Ward, 1995; U.S. food and Drug Administration, n.d., 
para 8). 
Characteristics and outcomes from published studies evaluating the efficacy and 
safety of nesiritide were used to define the heart failure patient. Conclusions were made 
and accepted based on database analysis of several heart failure registries developed 
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from the nesiritide studies. A conclusion supported by these registries is that when 
treatment is initiated early, outcomes improve, as is the case in other acute illnesses 
(Adams et al., 2003; Rivers et al., 2001; Rowe, Spooner, Ducharme, Bretzlaff, & Bota, 
2001; Vidt, 2001). Clinical characteristics and outcomes can be limited by the selection 
criteria used to study the safety and efficacy of specific investigational drugs or devices. 
Constraints on standard treatment options while on study are often inherent in clinical 
trials. For these reasons measurements of the causes of mortality and morbidity and 
readmission rates from randomized clinical trials cohorts may not provide external validity 
(Murray-Thomas & Cowie, 2003). 
Buiciuc et al. (2011) conducted a long-term study investigating the association 
between low systolic blood pressure and long-term mortality in patients newly diagnosed 
with heart failure and preserved ejection fraction. The authors state, “An epidemiologic 
approach was taken without the use of modelbuilding” (p. 909). Clinical data and 
laboratory testing results were used as measures of association to draw inferences 
concerning causal relationships between these events and the five year all-cause 
mortality rates. A low systolic blood pressure defined in this study as < 120 mmHg was 
linearly associated with a five year all-cause mortality and cardiovascular death. Future 
clinical research is needed to determine if standard of care blood pressure readings are 
useful in improving current risk stratification models. 
Investigators of the Organized Program to Initiate Lifesaving Treatment In 
Hospitalized Patients With Heart Failure (OPTIMIZE-HF) clinical trial suggests using a 
risk-prediction algorithm to identify patients who are at high risk of in-hospital mortality. 
Systolic blood pressure and six other multivariables were used in the scoring system to 
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predict mortality. Patients with high risk scores may be appropriate candidates for more 
aggressive monitoring and intervention than patients with average or low risk of in hospital 
death (Abraham et al., 2008). Alternatively, patients with low risk scores may be treated 
conservatively without exposure to additional risks from aggressive interventions. Risk-
prediction algorithms are medical calculators that are easy, quick, reliable, and rely on 
evidence-based medical guidelines to compute risk for decision-making to support 
healthcare delivery. Free and premium versions of mobile apps for risk calculation are 
increasing used in clinical practice. An example of a cardiology tool is the Framingham 
Risk Calculator that measures the 10 year coronary heart disease risk using seven simple 
questions (i.e., age, gender, total cholesterol, HDL cholesterol, smoking status, systolic 
blood pressure reading, and use of medication to treat hypertension). 
This restriction of range in selected patients, while providing homogeneity for 
analyzing the results of specified investigational drugs, may not mirror the average heart 
failure admitted for acute decompensated heart failure. Several trials exclude or limit entry 
of patients admitted with common comorbidities such atrial fibrillation, diabetes, or severe 
hypertension. A low systolic blood pressure often excludes patients either directly, or 
indirectly. Safety concerns with drugs that lower blood pressure result in exclusion of 
patients with a systolic blood pressure of less than 110 mmHg. Intravenously 
administered drugs such as inotropes or vasodilators used to treat patients with low 
systolic blood pressure indirectly exclude these patients. Thus the clinical characteristics 
of patients enrolled in clinical trials may differ significantly from patients encountered in 
the real-world clinical practice. 
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Use of Retrospective Data 
Evaluation of the disease course, prognosis and response to therapy over time is 
critically important to collect. Documentation dictated by national guidelines and required 
for reimbursement has standardized the information collected at each patient visit. 
The investigator starts with the disease or its outcome(s) and works backwards to 
find possible causes. Retrospective studies by definition are nonexperimental and play 
no role in assigning patients to treatment. Thus a cause and effect cannot be measured. 
Most IRBs will not require patient consent which avoids the Hawthorne Effect. The 
Hawthorne Effect refers to the phenomenon whereby a temporary change in behavior or 
performance occurs when people know they are being observed. 
There are many advantages of using existing data collected from electronic 
medical records. Prospectively collected new data is expensive, labor-, and time- 
intensive. The use of existing data allows a quicker, more efficient and less expensive 
source for data analysis. Large samples (N>1,000) can be realistically conducted in a 
short period of time. They can be analyzed to detect uncommon outcomes to provide 
odds ratios which are an estimate of relative risk. The data can be randomly sampled or 
used to create a cohort. In addition, data in an electronic query enabled format represents 
less chance of transcription errors and missing data than manual chart abstraction. 
Variables are stored in discrete fields in electronic medical records. Demographic 
information, laboratory results, administered inpatient drugs, outpatient prescriptions 
(used to measure compliance) and many other variables can be imported directly to other 
database platforms. Data recorded in clinical notes that are not in a designated numeric 
text field would need to be manual extracted. Although, data recognition software such 
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as Optical Character Recognition software (OCR software) translates text images into 
text read by computer may eventually eliminate the need for manual extraction. 
The use of existing data from various sources including financial and medical 
insurance coverage allows for more identifiers which may potentially illustrate 
relationships between variables that would otherwise not be determined. Results vary 
whether or not insurance benefit coverage is associated with improved health care 
outcomes (Fowler et al., 2010; Kapoor et al., 2011; B. S. Mann et al., 2014; Mansi, Shi, 
Altenburg, Mukoosa, & Huang, 2011). Existing knowledge can be reinforced by the data 
or prompt the need for change. Interestingly, retrospective collection of data performed 
without any consideration of the study may reduce the chance of unintentional bias. As 
stated earlier, there is an issue of generalizability or externality since prospective 
randomized clinical trials have restrictive entry criteria and a strict protocol must be 
followed (Rothwell, 2005). There is careful monitoring, adherence and follow-up inherent 
in the study schedule of visits. The question remains whether or not these results can be 
extrapolated to the general heart failure population. The selection of patients entered in 
a retrospective study is much looser and their care is often what is normally seen in clinical 
practice. 
Other pitfalls include clinical equipoise, refusal to be randomized, and early 
withdrawal. Clinical equipoise applies to randomized controlled trials that use placebos, 
an inferior comparator, or a comparator that exhibits inferiority at some point in the study. 
“Clinical equipoise, also known as the principle of equipoise, provides the ethical basis 
for medical research that involves assigning patients to different treatment arms of a 
clinical trial. The term was first used by Benjamin Freedman in 1987” (The Free 
DEVELOPMENT OF THE RISK MODEL FOR RESIDENT TRAINING 36 
 
 
 
Dictionary, para 1). Freedman, a bioethicist at the Clinical Trials Research Group at 
McGill University’s Biomedical Ethics unit wrote, “According to this concept of clinical 
equipoise, the requirement is satisfied if there is genuine uncertainty within the expert 
medical community - not necessarily on the part of the individual investigator - about the 
preferred treatment” (1987, p. 141). The ethical issue of clinical equipoise does not exist 
in retrospective studies since the treatment has occurred. The ethical concern over the 
fiduciary duty found in the Hippocratic Oath to do what is best for the patient rather than 
the physician may be in direct conflict of the randomization to treatment in the 
experimental design. A detailed discussion of clinical equipoise was beyond the scope of 
this paper. Also, this may not be particularly important in this paper as patients with low 
systolic blood pressure are often not entered in clinical trials either by design or by the 
decision of the clinical investigator for fear that the active arm may be deleterious to the 
patient’s health. 
As there are advantages to using existing data there are important disadvantages. 
Unlike prospective studies, treatments are not controlled or manipulated and since the 
activities have occurred in the past, measurement of outcomes is limited to what is 
documented. However, the data may not be suited to test the current research questions 
since it was collected for other purposes. Additionally it may be incomplete especially if 
there a variety of treating physicians or institutions. This may result in sampling bias. 
Other limitations include patient and treatment selection biases and this source of 
error is greater in retrospective studies compared to prospective studies. As more 
physicians abide by evidence-based guidelines set by the American Heart Association 
(AHA), American College of Cardiology (ACC), American Stroke Association (ASA), and 
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other organizations for cardiovascular care, this is less of an issue. Even so, these patient 
populations are less homogenous than those selected for prospective studies. 
Unmeasured factors can have an influence on treatment. Multivariable analysis can be 
used to attempt to control for these confounding variables or factors that threaten validity. 
In conclusion, every experiment is flawed. According to Campbell and Stanley 
(1966), 
From the standpoint of the final interpretation of an experiment and the 
attempt to fit it into the developing science, every experiment is imperfect. 
What a check list of validity criteria can do is to make an experimenter more 
aware of the residual imperfections in his design so that the relevant points 
he can be aware of competing interpretations of his data. He should, of 
course, design the very best experiment which the situation makes possible. 
(p. 34) 
Although Campbell and Stanley were not addressing the EFA approach, criticism of 
this method stems from the series of steps and decisions least understood by most 
investigators. There is no hypothesis. Instead, relationships among variables are 
explored to identify patterns and the number of factors to be estimated will not be 
specified a priori but determined based on what the data show. Therefore, the next 
chapter details the choices and assumptions made at each step of the process 
combining the steps of EFA with the literature reviewed. 
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CHAPTER 3 METHODOLOGY 
Purpose of the Study 
The purpose of this study was to characterize patients hospitalized with acute 
decompensated heart failure with and without low systolic blood pressure using factor 
analysis. A better understanding of the characteristics and outcomes of patients 
presenting with acute decompensated heart failure with and without low systolic blood 
pressure can potentially lead to individualized treatment modalities tailored to effectively, 
and economically improve care. 
Research Questions 
1. What were the common factors in patients with acute decompensated heart 
failure? 
2. What were the common factors in patients with acute decompensated heart failure 
and normal or high systolic blood pressure? 
3. What were the common factors in patients with acute decompensated heart failure 
and low systolic blood pressure? 
4. Was there a difference in the common factors in patients with and without low 
systolic blood pressure and acute decompensate heart failure? 
  
DEVELOPMENT OF THE RISK MODEL FOR RESIDENT TRAINING 39 
 
 
 
Setting 
The study site was a large urban, academic teaching hospital in the heart of the 
city just west of a major freeway in Detroit, Michigan. The original hospital built in 1915 
by Henry Ford was initially staffed mostly by physicians and surgeons from Johns Hopkins 
Hospital. The Detroit campus services the Detroit metropolitan area. The emergency 
room became an independent department in 1982, and in 2006, it was expanded and 
renovated as a part of $90 million expenditure. The 38,000 square foot emergency 
department provides care to approximately 93, 000 patients annually and accounts for 44 
percent of all hospital admissions (Henry Ford Health System, n.d.-b). 
The study site was located in one of the six hospitals of a system that includes 
specialty programs and medical centers which comprises Michigan’s largest mixed model 
managed care plan. As Michigan’s fifth largest employer with more than 23,000 
employees, the system accounts for more than an annual economic stimulus of $1.7 
billion (Henry Ford Health System, n.d.-a) . 
Special features of the department include two major resuscitation rooms, a 16 
bed critical care area and centralized nursing stations allowing for maximum visibility of 
patients with improved efficiency and traffic flow for staff (Henry Ford Health System, n.d.-
c). Medical personal include 30 senior staff physicians, 52 residents, over 300 registered 
nurses, and other support personnel such as pharmacists, physician assistants, and 
medical technicians. The emergency department includes an onsite pharmacy, active 
research programs and since 1976, an emergency medicine resident education program. 
Clinical pharmacy services in the emergency department are associated with increased 
safety, decreased cost, and improved outcomes (Cohen, Jellinek, Hatch, & Motov, 2009; 
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Fairbanks, Hays, Webster, & Spillane, 2004). Industry, governmental and investigator 
initiated research investigating heart failure biomarkers and congestive heart failure 
research is conducted or initiated in the emergency department. Training programs for 
medical students, registered nurses, physician assistants and emergency medical 
services personnel from the University of Michigan, Wayne State University, and over 20 
other U. S. medical schools are housed in the emergency department. 
Internal Review Board Approval 
The institutional review board of record was located at the study site and the 
Wayne State University Human Investigation Committee was the internal review board 
for the University. In accordance of the Code of Federal Regulations on human subjects 
research (45 CFR §46 and 21 CFR §56. 110), the initial review qualified for expedited 
review, “(1) some or all of the research appearing on the list and found by the reviewer(s) 
to involve no more than minimal risk” (U.S. Department of Health and Human Services, 
n.d., Section §46.110). The condition this study met was number five, “Research involving 
materials (data, documents, records, or specimens) that have been collected, or will be 
collected solely for nonresearch purposes (such as medical treatment or diagnosis)” (U.S. 
Department of Health and Human Services, n.d., para 11). The expedited approval letters 
are found in appendices C and D. 
Collaborative Institutional Training Initiative by the researcher for good clinical 
practice, information privacy and security, human subjects research and responsible 
conduct of research certification as required by the site’s and the University’s internal 
review are found in appendices G and H (CITI Program, n.d.). 
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Cases 
Eligible cases were patients hospitalized with a primary diagnosis of acute 
decompensated heart failure at the study site from January 1, 2014 to October 31, 2014 
with an International Classification of Diseases, Ninth Revision, Clinical Modification code 
428 (refer to Appendix I). The diagnosis of acute decompensated heart failure was 
established by the presence of typical symptoms, signs, and objective evidence of 
pulmonary congestion, elevated b-type natriuretic peptide or impaired cardiac function 
(Fonarow, Peacock, Phillips, Givertz, & Lopatin, 2007; Gheorghiade & Ruschitzka, 2011; 
Harinstein et al., 2011; Joseph et al., 2009; Michtalik et al., 2011; Murray-Thomas & 
Cowie, 2003; Varughese, 2007). All entry criteria (exclusion and inclusion) were met. 
Case selection was not based on race, ethnic or gender criteria.  
In compliance to Health Insurance Portability and Accountability Act of 1996 
(HIPAA), the legal conditions for a waiver of authorization were met (U.S. Department of 
Health and Human Services, n.d.). Protected health information collected but not 
disclosed were elements of dates and medical record numbers. There was no more than 
minimal risk of privacy from the use of protected health information since only the 
investigator had access to the link between the participant’s medical record number and 
the coded identifier used in the database (the term participant rather than case is used in 
this section). The link was maintained in an electronic format in a password protected 
computer accessible only to the investigator. A second security measure was employed 
to secure and prevent opening of the file by using password protection. The data analysis 
was performed only on the de-linked data. The data were overridden and permanently 
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deleted six months after the final close-out of the study with the site’s and the University’s 
internal review board. 
This research could not practically be conducted without the waiver of 
authorization since dates and medical record numbers are required for data evaluation. 
No further gain either to the research study or to the participant would result and 
conversely, there was a potential increased risk of emotional stress if the participant was 
contacted or approached to consent (Schuck, 1994). 
Description of the data set. Variables collected were identified based on review 
of the literature, Framingham criteria, clinical relevance, and were routinely availability 
upon the first 24 hours of hospital presentation and throughout hospitalization until 
discharge. Variables selected for abstraction were further guided by the writer’s extensive 
research experience and clinical expertise. Descriptive variables include gender, race, 
heart failure etiology and implantable device(s) used to treat heart failure or its associated 
symptoms such as an implantable cardioverter-defibrillator or a cardiac resynchronization 
therapy defibrillator. Variables listed in Table 3 were used for data analysis using the 
guidelines for EFA include ordinal, interval and ratio data. Ordinal data include the New 
York Heart Association functional class (before hospitalization) and interval data include 
left ventricular ejection fraction. Ratio data include heart rate, serum laboratory results 
and total IV diuretic dosage during hospitalization. 
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Entry Criteria 
Inclusion 
1. men or women aged 18-89 years 
2. hospitalized for management of acute decompensated heart failure defined as, 
a. dyspnea at rest or with minimal activity (i.e. , difficulty breathing at rest 
while shitting, or difficulty breathing while lying flat or with 1 pillow, or 
difficulty breathing with minimal activity such as talking or eating) 
b. requiring intravenous treatment with loop diuretic (i.e. , furosemide) 
Exclusion 
1. 24 hour or less admission defined as discharge from hospital within 24 hours 
or less (including clinical decision unit at study site) 
2. developed heart failure after admission or transferred from another acute care 
facility 
3. advanced AHA stage D CHF requiring consideration for heart transplant, 
mechanical assisting devices, or chronic inotropic therapy 
4. heart failure due to, 
a. myocarditis and cardiomyopathies due to inflammation 
b. congenital 
c. cardiotoxicity related to cancer (chemo- or radiation induced), 
alcoholic and/or cocaine induced cardiomyopathy permitted 
d. pregnancy (peripartum/postpartum) 
5. planned transfer to hospice care or other end-of-life care 
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6. planned cardiac surgery or coronary intervention (i.e., angioplasty with or 
without stenting) at index hospitalization 
7. participating in an investigational drug or device clinical trial or behavioral 
modification study during hospitalization (biomarker study participation 
permitted) 
8. concurrent treatments or conditions including, 
a. end stage renal disease and/or current dialysis treatment 
b. current chemo- or radiation therapy 
c. pregnancy 
Pregnancy. Normal hemodynamic changes in pregnancy include an increase in 
blood volume, heart rate, and cardiac output, a decrease in blood pressure and systemic 
vascular resistance, and changes in stroke volume due to the growing fetus. A patient 
with heart failure may be more compromised hemodynamically when pregnant and the 
variables collected in this study may be very different compared to the target group. An 
example of such variable is the dosage of angiotensin converting enzyme inhibitors or 
angiotensin receptor blockers. While treatment with either an angiotensin converting 
enzyme or angiotensin receptor blocker is a standard guideline treatment in patients with 
heart failure, both of these medications are contraindicated in pregnancy (Siu et al., 2001; 
Thorne, 2004). 
Sampling. EpicCare EMR by Epic Systems Incorporated is an excellent user 
interface allowing reports to be exported to other software applications without requiring 
programming language by the user. Although there is a lag time, real-time data is not 
required for the retrospective chart review design of this study. 
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After internal review approval, an online service request order was placed and 
routed to the senior performance measurement analyst in the department of operational 
analytics at the study site. An Epic report using the variables of interest was run for the 
study dates January 1, 2014 to October 31, 2014 for patients in the emergency room a 
primary ICD-9 diagnosis code of 428 (heart failure, see Appendix J and K) who were 
subsequently admitted. The raw data was used to build the database. The variables 
extracted were visually inspected to detect any data quality problems and cleaned. Only 
eligible cases were retained in sequential order of emergency room presentation. Missing 
data was evaluated and the data was further cleaned by eliminating cases without 
documentation of core variables. This was most prominent in patients whose past medical 
records were retained at an outside institution (e.g., echocardiogram results). 
Non structured data, that is, data not found in discrete fields was manually 
abstracted. This data was not structured or actionable since it was embedded in a report 
that was uploaded rather than imported to the electronic medical record from the original 
program such as Siemens Syngo® radiology imaging software. 
It was expected up to 500-600 patients were hospitalized with congestive heart 
failure over the nine month research time period. The first 300 cleaned records were 
retained for the group EFA addressing research question number 1. 
 What were the common factors in patients with acute decompensated heart 
failure? 
The first 150 cleaned records for each of the groups were retained for EFA for the low 
and normal or high systolic blood pressure group EFA addressing research questions 
number 2 and 3. 
DEVELOPMENT OF THE RISK MODEL FOR RESIDENT TRAINING 47 
 
 
 
 What were the common factors in patients with acute decompensated heart 
failure and normal or high systolic blood pressure? 
 What were the common factors in patients with acute decompensated heart 
failure and low systolic blood pressure? 
The factors extracted in each of the groups were compared and described. 
Sample Size. As is the case in empirical studies, determining sample size in EFA, 
a large sample size technique, is based on the minimum necessary to obtain reliable 
results from the analysis.  Comrey and Lee (1992) state, 
Correlation coefficients tend to be less reliable when estimated from small 
samples.  There, it is important that sample size be large enough that 
correlations are reliably estimated.  The required sample size also depends 
on magnitude of population correlations and number of factors: if there are 
strong correlation and a few, distinct factors, a smaller sample size is 
adequate. (p. 618) 
Guidelines or a rule of thumb by expert opinions such as Gorsuch (1983) and Kline (1994) 
include absolute numbers of at least 100 cases. Comrey and Lee (1992) recommended 
a scale such that 50 is very poor, 100 is poor, 200 is fair, 300 is good, 500 is very good 
and 1,000 or more is excellent. Others proposed minimum ratios of number of variable to 
cases (n:p). Cattell (1978) recommended three to six cases (or subjects) per variable, 
Gorsuch (1983) recommended a ratio of at least five and Nunnally (1978) recommended 
at least ten times as many cases as variables. An easy to follow detailed discussion of 
sample size is found in an article by (MacCallum, Widaman, Zhang, & Hong, 1999). 
Data Management 
There were three separate spreadsheets using Microsoft Excel software PC 
version. The first was a spreadsheet containing the Epic report data. Manually abstracted 
data were added to this spreadsheet. The second was a spreadsheet containing the link 
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between the abstracted cases that included the medical record number of the cases and 
the coded identifier or study case number. The third was the fully abstracted data where 
the medical record number was replaced by the study case number. This latter 
spreadsheet was imported to the Statistical Package for the Social Sciences® (SPSS) for 
Windows™, Student Version, Personal Computer Version, v. 17 for data analysis. To 
ensure confidentiality, access to the Epic report and the spreadsheet containing the link 
between cases was limited to the principal investigator. 
An algorithm of the study design flow from the study proposal phase to the end of 
the study as in Figure 4 followed by a description and justification of the EFA approach 
completes the methodology followed in this study. 
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Figure 4 Study Process Algorithm 
Data Analysis 
EFA is heuristic and used to discover summary constructs when their nature is still 
unknown. Using a subset of variables that correlate with each other but which are mostly 
independent of other variables, EFA combines these variables into factors. “Factor 
analysis consists of a number of statistical techniques the aim if which is to simplify 
complex sets of data” (Kline, 1994, p. 3). The multivariate approach using EFA to create 
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composite factor scores is appropriate as listed by Hair et al. (1992) in their fourth purpose 
of this method, “Create an entirely new set of a smaller number of variables to partially or 
completely replace the original set of variables for inclusion in subsequent regression, 
correlation, or discriminate analysis” (p. 226). The model is not specified a priori, the 
number of latent variables is not specified a priori and all latent variables affect all 
observed variables. EFA performed in the early stages of research does not require a 
potential theoretical basis for selection of the variables of interest (Tabachnick & Fidell, 
2013). 
EFA run on the desired variables produced a data matrix. A correlation matrix was 
used for EFA rather than a covariance matrix traditionally used for confirmatory factor 
analysis. Each case was represented in a row and each variable was represented in a 
column and the resulting matrix has N rows and K columns. The correlation matrix was 
computed resulting in a square and symmetric mirror image along its diagonal of K rows 
and K columns. The factor matrix is a linear combination of the common factors and a 
unique factor that contains error variability and variability of the specific variable. A 
pictorial representation of the each matrix in the EFA process is exhibited in the following 
figure. 
 
Figure 5 Matrix Process in EFA 
Variable 1  … Variable k Variable 1  … Variable k Factor 1  … Factor k
Case 1 Variable 1 Variable 1 
.  …  …
. Variable k
. Variable k
Case n
Diagonal - all correlations =1
Distinctive cells =  K x (K - 1) / 2 
Data Matrix Correlation Matrix Factor Matrix
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For simplicity, suppose 2 factors were determined in the sample used to address 
research question number 3. 
 What were the common factors in patients with acute decompensated heart 
failure and low systolic blood pressure? 
These factors represent unobservable latent variables. Patients with decompensated 
heart failure with a low systolic blood pressure and several other measureable 
evaluations, signs and symptoms were seen in the emergency room. Let the other 
measureable evaluations, signs and symptoms be represented by the term heart failure 
variables. Such a patient randomly selected from a large population would also have a 
random set of heart failure variables. The average score in each of the heart failure 
variables for a patient with a particular level of factor one and a particular level of factor 
two is x multiplied by factor one plus y multiplied by factor two. This is a linear combination 
of the two factors (see below). The x and y values, or factor loadings are the same for 
other patients with heart failure who present to the emergency room with decompensated 
heart failure and a low systolic blood pressure (Ivancevic & Ivancevic, 2007, p. 50). 
|(x,y)| ≤ ||x||·||y||  (1) 
The seven stages in factor analysis design will be employed in this analysis. 
According to Hair et al. (2006) the stages are: 
State 1: Objectives 
Stage 2: Designing Factor Analysis 
Stage 3: Assumptions in Factor Analysis 
 5 variables for each factor 
 Sample must have more observations than variable 
(minimum N=50) 
 Maximize the number of observations per variable (10 
or more) 
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 Assess data and perform pairwise deletion of missing 
data or imputation with overall mean if missing data are 
not too numerous 
 A strong conceptual foundation need to support the 
assumption that a structure does exist before the factor 
analysis is performed 
 A statistically significant Bartlett’s test of sphericity (sig 
>0. 05) indicates that sufficient correlations exist 
among the variable to proceed 
 Cronbach alpha, a measure of sampling adequacy 
(MSA) values must exceed 0. 50 for both the overall 
test and each individual variable 
Stage 4: Deriving Factors and Assessing overall Fit 
 Choosing a model 
 Criteria for number of factors to extract 
 Latent root criteria 
 Scree Test Criterion 
Stage 5: Selecting a Rotational Method 
 Assess Communalities 
Stage 6: Validation of Factor Analysis 
 Use of a confirmatory perspective 
 Assessing Factor Structure Stability 
Stage 7: Additional Uses of Factor Analysis results. 
(pp. 108-116) 
Cronbach defined Cronbach alpha as, “shown to be the mean of all split-half 
coefficients resulting from different splittings of a test. Alpha is therefore an estimate of 
the correlation between two random samples of items from a universe of items like 
those in the test.  Alpha is found to be an appropriate index of equivalence and, except 
for very short tests, of the first-factor concentration in the test.” (Cronbach, 1951, p. 
297).  By splitting the data randomly, the data is split in two in every possible way and 
the correlation coefficient for each split is computed.  The average of the values 
obtained used as an index of reliability, Cronbach’s alpha, is the most common measure 
of scale reliability.  This value estimates the amount of measurement error in a test. The 
correlation is squared and subtracted from one to produce the index of measurement 
error. Factor 8 has a reliability of 0.687 (α=0.687) and therefore there is a 0.528031 
DEVELOPMENT OF THE RISK MODEL FOR RESIDENT TRAINING 53 
 
 
 
variance or random error in values (variables abstracted) (0.687 * 0.687 = 0.471969; 
1.00 – 0.471969 = 0.528031).  The measurement error for Factor 9 is 0.605616 
indicating that as the estimate of reliability decreases, the fraction of a value (variable) 
that is attributable to error will increase and vice-versa.  The reliability of a variable is 
measured on the full cohort of patients rather than on one individual patient. 
The computational formula for the standardized Cronbach's alpha: 
 
Where N is equal to the number of items, c-bar is the average inter-item 
covariance among the items and v-bar equals the average variance. 
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CHAPTER 4 RESULTS 
Dimension reduction of factors via SPSS (ver 23) was conducted on all cases 
regardless of presenting systolic blood pressure (Group 1), cases with normal to high 
systolic blood pressure (Group 2) and cases with low systolic blood pressure (Group 3) 
separately, for a total of groups.  The descriptive options for the correlation matrix 
requested was coefficients, significance levels, determinant and KMO and Bartlett’s test 
of sphericity.  The method employed was principal components and the analysis of the 
correlation method was selected.  The scree plot and Eigenvalues greater than 1 with a 
maximum of 250 iteration for convergence were selected.  The rotation method selected 
was Varimax with a maximum of 250 iterations.  Varimax, an orthogonal rotation 
method was chosen since it produces independent factors minimizing the number of 
variables that have high loadings on each factor resulting in a solution with no 
multicollinearity. Thus the interpretation of the factors is simplified. Score options for 
variables selected were Bartlett and display of the factor score coefficient matrix.  
Options selected were to replace missing values with the mean, sorting the coefficient 
by size and suppressing coefficients less than |.4|. 
The initial analysis resulted in correlation matrices that were not positive 
definitive.  A second analysis was conducted by removing all variables with linear 
dependency defined as 1.0 on the inter-item correlation matrix when each of the 
resulting factors were run for a reliability analysis using the alpha model.  Variables that 
loaded on more than one factor, with a factor loading less than |.4|, or did not load were 
removed.  Missing data were replaced with the mean which may have contributed to 
linear dependency. 
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Initial Analysis 
Group 1:  All Cases Regardless of Systolic Blood Pressure at Presentation
 
Figure 6 Scree Plot All Cases Regardless of Systolic Blood Pressure at Presentation 
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Table 6 
Group 1Total Variance Explained for All Cases Regardless of Systolic Blood Pressure 
at Presentation 
Component 
Extraction Sums of Squared 
Loadings 
Rotation Sums of Squared 
Loadings 
Total 
% of 
Variance 
Cumulati
ve % Total 
% of 
Variance 
Cumulati
ve % 
1 5.067 13.333 13.333 4.721 12.422 12.422 
2 3.922 10.321 23.654 3.756 9.885 22.307 
3 3.223 8.480 32.135 3.087 8.124 30.431 
4 3.097 8.150 40.284 2.593 6.823 37.254 
5 2.761 7.266 47.550 2.423 6.376 43.630 
6 2.650 6.974 54.524 2.350 6.185 49.815 
7 2.463 6.483 61.007 2.170 5.711 55.525 
8 2.157 5.677 66.684 2.069 5.444 60.969 
9 1.972 5.189 71.873 2.060 5.421 66.390 
10 1.774 4.669 76.542 2.038 5.363 71.753 
11 1.523 4.008 80.551 2.012 5.295 77.049 
12 1.384 3.643 84.194 1.999 5.262 82.310 
13 1.177 3.098 87.292 1.893 4.982 87.292 
Extraction Method: Principal Component Analysis. 
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Table 7 
Rotated Component Matrix for All Cases Regardless of Systolic Blood Pressure at 
Presentation 
 
 
Component 
1 2 3 4 5 6 7 8 9 10 11 12 13 
Low Hematocrit .978             
High Hematocrit .978             
Low Hemoglobin .957             
High RBC_Count .932             
Low RBC_Count .932             
Low Eosinophils, 
Absolute 
 .966            
High Eosinophils, 
Absolute 
 .966            
High Eosinophils – 
Rel (Diff) 
 .964            
Low Eosinophils – 
Rel (Diff) 
 .964            
High PT   .989           
Low PT   .989           
Low INR   .987           
SBP    .746          
Abnormal_Labs    .741          
DBP    .669          
Co-morbidity    .656          
Readmission_12 
Mos 
   .580          
Ethnicity    -.477          
Low 
Mean_Corpuscula
r+ Hemoglobin 
    .983         
High 
Mean_Corpuscula
r_ Hemoglobin 
    .983         
High Troponin I      .945        
Tropinin      .930        
LVEDd      .758        
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Component 
 1 2 3 4 5 6 7 8 9 10 11 12 13 
Lowco2       .953       
Carbon dioxide       .953       
Low Basophils – 
Abs (Diff) 
       .970      
High Basophils – 
Abs (Diff) 
       .970      
High WBC_Count         .980     
Low WBC_Count         .980     
Low Sodium          .987    
High Sodium          .987    
High Lymphocytes 
- Abs(Diff) 
          .972   
Low Lymphocytes 
– Abs (Diff) 
          .972   
Creatinine            .973  
Low creatinine            .973  
              
Illicit Drug 
(cocaine, heroin, 
etc., marjiuana not 
included) 
            .774 
alcholol_abuse             .756 
illicit drug 
(marijuana) 
            .740 
Note: Extraction Method: Principal Component Analysis.  
 Rotation Method: Varimax with Kaiser Normalization. 
 
Group 1:  All Cases Regardless of Systolic Blood Pressure at Presentation 
Table 8 
Group 1 Factor 1 for Inter-Item Correlation Matrix for All Cases Regardless of Systolic 
Blood Pressure at Presentation 
 
 Low Hemotocrit 
High 
Hemotocrit 
Low 
Hemoglobin 
High 
RBC_Count 
Low 
RBC_Count 
Low Hemotocrit 1.000 1.000 .987 .864 .864 
High Hemotocrit 1.000 1.000 .987 .864 .864 
Low Hemoglobin .987 .987 1.000 .817 .817 
High RBC_Count .864 .864 .817 1.000 1.000 
Low RBC_Count .864 .864 .817 1.000 1.000 
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Table 9 
Reliability Statistics for All Cases Regardless of Systolic Blood Pressure at Presentation 
Group 1 Factor 1 Anemia 
 
Reliability Statistics 
Cronbach's 
Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.836 .980 5 
 
Table 10 
Inter-Item Correlation Matrix for All Cases Regardless of Systolic Blood Pressure at 
Presentation 
Group 1 Factor 2 Heart Injury Lab Predictor 
 
 
High 
Eosinophils 
- Rel (Diff) 
High 
Eosinophils, 
Absolute 
Low 
Eosinophils - 
Rel (Diff) 
Low 
Eosinophils, 
Absolute 
High Eosinophils - Rel 
(Diff) 
1.000 .870 1.000 .870 
High Eosinophils, 
Absolute 
.870 1.000 .870 1.000 
Low Eosinophils - Rel 
(Diff) 
1.000 .870 1.000 .870 
Low Eosinophils, 
Absolute 
.870 1.000 .870 1.000 
 
Table 11 
Reliability Statistics for All Cases Regardless of Systolic Blood Pressure at Presentation 
Group 1 Factor 2 Heart Injury Lab Predictor 
 
Cronbach's 
Alpha 
Cronbach's Alpha Based 
on Standardized Items N of Items 
.754 .977 4 
 
Table 12 
Inter-Item Correlation Matrix for All Cases Regardless of Systolic Blood Pressure at 
Presentation 
Group 1 Factor 3 Coagulopathy 
 HighPT Low PT Low INR 
High PT 1.000 1.000 .987 
Low PT 1.000 1.000 .987 
Low INR .987 .987 1.000 
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Table 13 
Reliability Statistics for All Cases Regardless of Systolic Blood Pressure at Presentation 
Group 1 Factor 3 Coagulopathy 
Cronbach's 
Alpha 
Cronbach's Alpha Based 
on Standardized Items N of Items 
.836 .997 3 
 
Table 14 
Inter-Item Correlation Matrix for All Cases Regardless of Systolic Blood Pressure at 
Presentation 
Group 1 All Factor 4 Severity 
 SBP Abnormal_Labs DBP 
Co-
morbidity 
Readmission
_12 Mos Ethnicity 
SBP 1.000 .381 .637 .264 .208 -.245 
Abnormal_Labs .381 1.000 .281 .447 .461 -.309 
DBP .637 .281 1.000 .221 .151 -.276 
Co-morbidity .264 .447 .221 1.000 .422 -.219 
Readmission_ 
12 Mos 
.208 .461 .151 .422 1.000 -.256 
Ethnicity -.245 -.309 -.276 -.219 -.256 1.000 
 
Table 15 
Reliability Statistics for All Cases Regardless of Systolic Blood Pressure at Presentation 
Group 1 All Factor 4 Severity 
 
Cronbach's Alpha 
Cronbach's Alpha Based 
on Standardized Items N of Items 
.466 .503 6 
 
Table 16 
Inter-Item Correlation Matrix for All Cases Regardless of Systolic Blood Pressure at 
Presentation 
Group 1 Factor 5 Hemoglobin Kidney Injury 
 
HighMEAN_CORPUSCULAR_ 
Hemoglobin 
LowMEAN_CORPUSCULAR 
Hemoglobin 
Highmean_Corpuscular_ 
Hemoglobin 
1.000 1.000 
Lowmean_Corpuscular_ 
Hemoglobin 
1.000 1.000 
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Table 17 
Reliability Statistics for All Cases Regardless of Systolic Blood Pressure at Presentation 
Group 1 Factor 5 Hemoglobin Kidney Injury 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
1.000 1.000 2 
 
Table 18 
Inter-Item Correlation Matrix for All Cases Regardless of Systolic Blood Pressure at 
Presentation 
Group 1 Factor 6 Heart Injury 
 High Troponin I Tropinin LVEDd 
High Troponin I 1.000 .999 .558 
Tropinin .999 1.000 .559 
LVEDd .558 .559 1.000 
 
Table 19 
Reliability Statistics for All Cases Regardless of Systolic Blood Pressure at Presentation 
Group 1 Factor 6 Heart Injury 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.069 .878 3 
 
Table 20 
Inter-Item Correlation Matrix for All Cases Regardless of Systolic Blood Pressure at 
Presentation 
Group 1 Factor 7 Electrolyte Kidney Injury 
 
 LowCO2 Carbon Dioxide 
Low CO2 1.000 1.000 
Carbon Dioxide 1.000 1.000 
 
Table 21 
Reliability Statistics for All Cases Regardless of Systolic Blood Pressure at Presentation 
Group 1 Factor 7 Electrolyte Kidney Injury 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
1.000 1.000 2 
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Table 22 
Inter-Item Correlation Matrix for All Cases Regardless of Systolic Blood Pressure at 
Presentation 
Group 1 Factor 8 Inflammation B 
 
 
High Basophils - 
Abs (Diff) 
Low Basophils - Abs 
(Diff) 
High Basophils - Abs(Diff) 1.000 1.000 
Low Basophils - Ab (Diff) 1.000 1.000 
 
Table 23 
Reliability Statistics for All Cases Regardless of Systolic Blood Pressure at Presentation 
Group 1 Factor 8 Inflammation B 
 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
1.000 1.000 2 
 
Table 24 
Inter-Item Correlation Matrix for All Cases Regardless of Systolic Blood Pressure at 
Presentation 
Group 1 Factor 9 Incidental Hypertension 
 
 High WBC_Count Low WBC_Count 
High WBC_Count 1.000 1.000 
Low WBC_Count 1.000 1.000 
 
Table 25 
Reliability Statistics for All Cases Regardless of Systolic Blood Pressure at Presentation 
Group 1 Factor 9 Incidental Hypertension 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
1.000 1.000 2 
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Table 26 
Inter-Item Correlation Matrix for All Cases Regardless of Systolic Blood Pressure at 
Presentation 
Group 1 Factor 10 Natremia 
 
 
 High Sodium Low Sodium 
High Sodium 1.000 1.000 
Low Sodium 1.000 1.000 
 
Table 27 
Reliability Statistics for All Cases Regardless of Systolic Blood Pressure at Presentation 
Group 1 Factor 10 Natremia 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
1.000 1.000 2 
 
Table 28 
Inter-Item Correlation Matrix for All Cases Regardless of Systolic Blood Pressure at 
Presentation 
Group 1 Factor 11 Inflammation L 
 
 
High Lymphocytes – 
Abs(Diff) 
Low Lymphocytes – 
Abs(Diff) 
High Lymphocytes – Abs(Diff) 1.000 1.000 
Low Lymphocytes – Abs(Diff) 1.000 1.000 
 
Table 29 
Reliability Statistics for All Cases Regardless of Systolic Blood Pressure at Presentation 
Group 1 Factor 11 Inflammation L 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
1.000 1.000 2 
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Table 30 
Inter-Item Correlation Matrix for All Cases Regardless of Systolic Blood Pressure at 
Presentation 
Group 1 Factor 12 Kidney Injury 
 
 
 Creatinine Low Creatinine 
Creatinine 1.000 1.000 
Low Creatinine 1.000 1.000 
 
Table 31 
Reliability Statistics for All Cases Regardless of Systolic Blood Pressure at Presentation 
Group 1 Factor 12 Kidney Injury 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
1.000 1.000 2 
 
Table 32 
Inter-Item Correlation Matrix for All Cases Regardless of Systolic Blood Pressure at 
Presentation 
Group 1 Factor 13 Abuse 
 
 
Tobacco_
Abuse 
alcholol_
abuse 
Illicit Drug (cocaine, 
heroin, etc., 
marijuana not 
included) 
Illicit Drug 
(marijuana) 
Tobacco_Abuse 1.000 .350 .291 .298 
alcholol_abuse .350 1.000 .419 .390 
Illicit Drug (cocaine, 
heroin, etc., marjuana 
not included) 
.291 .419 1.000 .391 
Illicit Drug(marjuana) .298 .390 .391 1.000 
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Table 33 
Reliability Statistics for All Cases Regardless of Systolic Blood Pressure at Presentation 
Group 1 Factor 13 Abuse 
 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
0.654 .689 4 
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Group 2 All Cases with Normal to High SBP at Presentation 
Table 34. Group 2 Rotated Component Matrix for Cases with Normal to High Systolic 
Blood Pressure at Presentation 
 
 
Component 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
High Hemotocrit .982               
Low Hemotocrit .982               
HgB .966               
Low Hemoglobin .966               
Low RBC_Count .916               
High RBC_Count .916               
BUN  .912              
Low BUN  .912              
Creatinine  .887              
Low Creatinine  .887              
Mag  .541              
Low Eosinophils – 
Rel (Diff)  
  .963             
High  Eosinophils - 
Rel (Diff) 
  .963             
High  Eosinophils, 
Absolute 
  .962             
Low Eosinophils, 
Absolute 
  .962             
High PT    .990            
Low PT    .990            
Low INR    .985            
Chloride     .943           
Low Chloride     .943           
Low Sodium     .857           
Low Basophils – Abs 
(Diff) 
     .949          
High Basophils – Abs 
(Diff) 
     .949          
High Basophils - Rel 
(Diff) 
     .873          
Low CO2       .930         
Carbon Dioxide       .930         
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Component   
   
 1 2 3 4 5 6 7 8 9 10 11 12 13 14  
Anion_Gap       -
.642 
        
Mean_Corpuscul
ar_ Hemoglobin 
       .973        
Low 
Mean_Corpuscul
ar_ Hemoglobin 
       .973        
Low WBC_Count         .970       
High 
WBC_Count 
        .970       
High 
Platelet_Count 
        .529       
SBP          .763      
DBP          .750      
Co-morbidity          .582      
Pre-admission 
med – diuretic 
         .556      
Ethnicity          -.497      
Potassium           .952     
High Potassium           .952     
Discharge_ARB            .979    
Admit_ARB            .976    
Gender             .667   
Age             -.553   
Pain Score 
(Category List) 
            .539   
Anion Gap              .681  
Race              -.641  
RR               .661 
Preadmit_Thiazid
e_Diuretic 
              -.609 
Low ALT(SGPT)               .476 
Extraction Method: Principal Component Analysis.  
 Rotation Method: Varimax with Kaiser Normalization. 
a. Rotation converged in 7 iterations. 
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Figure 7 Scree Plot Cases with Normal to High Systolic Blood Pressure at Presentation 
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Table 35 
Group 2 Total Variance Explained for Cases with Normal to High Systolic Blood 
Pressure at Presentation 
 
Component 
Rotation Sums of Squared Loadings 
Total % of Variance Cumulative % 
1 5.688 11.609 11.609 
2 3.939 8.038 19.647 
3 3.814 7.784 27.431 
4 3.022 6.167 33.598 
5 2.786 5.686 39.284 
6 2.668 5.444 44.728 
7 2.613 5.332 50.061 
8 2.592 5.290 55.351 
9 2.396 4.889 60.240 
10 2.359 4.815 65.055 
11 2.154 4.395 69.450 
12 1.967 4.015 73.465 
13 1.377 2.809 76.274 
14 1.268 2.588 78.862 
15 1.197 2.443 81.305 
Note: Extraction Method: Principal Component Analysis. 
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Table 36 
Inter-Item Correlation Matrix for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 1 Anemia 
 
 
High 
Hemotocrit 
Low 
Hemotocrit HgB 
Low 
Hemoglobin 
Low 
RBC_Count 
High Hemotocrit 1.000 1.000 .987 .987 .864 
Low Hemotocrit 1.000 1.000 .987 .987 .864 
HgB .987 .987 1.000 1.000 .817 
Low Hemoglobin .987 .987 1.000 1.000 .817 
Low RBC_Count .864 .864 .817 .817 1.000 
 
Table 37 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 1 Anemia 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.884 .985 5 
 
Table 38 
Inter-Item Correlation Matrix for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 2 Kidney Injury 
 
 BUN Low BUN Creatinine Low Creatinine Mag 
BUN 1.000 1.000 .754 .754 .505 
Low BUN 1.000 1.000 .754 .754 .505 
Creatinine .754 .754 1.000 1.000 .327 
Low Creatinine .754 .754 1.000 1.000 .327 
Mag .505 .505 .327 .327 1.000 
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Table 39 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 2 Kidney Injury 
 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.674 .910 5 
 
Table 40 
Inter-Item Correlation Matrix for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 3 Heart Injury Lab Predictor 
 
Low 
Eosinophils - 
Rel (Diff) 
High 
Eosinophils - 
Rel (Diff) 
High 
Eosinophils, 
Absolute 
Low 
Eosinophils, 
Absolute 
Low Eosinophils - Rel (Diff) 1.000 1.000 .870 .870 
High  Eosinophils - Rel (Diff) 1.000 1.000 .870 .870 
High  Eosinophils, Absolute .870 .870 1.000 1.000 
Low Eosinophils, Absolute .870 .870 1.000 1.000 
 
Table 41 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 3 Heart Injury Lab Predictor 
 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.754 .977 4 
 
Table 42 
Inter-Item Correlation Matrix for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 4 Coagulopathy 
 
 High PT Low PT Low INR 
High PT 1.000 1.000 .987 
Low PT 1.000 1.000 .987 
Low INR .987 .987 1.000 
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Table 43 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 4 Coagulopathy 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.836 .997 3 
 
Table 44 
Inter-Item Correlation Matrix for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor Electrolyte Imbalance 
 
 Chloride Low CHLORIDE Low Sodium 
Chloride 1.000 1.000 .729 
Low Chloride 1.000 1.000 .729 
Low Sodium .729 .729 1.000 
 
Table 45 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 5 Electrolyte Imbalance 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.932 .931 3 
 
Table 46 
Inter-Item Correlation Matrix for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 6 Inflammation B 
 
 
Low Basophils _ Abs 
(Diff) 
High Basophils – 
Abs (Diff) 
High Basophils - 
Rel (Diff) 
Low Basophils _ Abs 
(Diff) 
1.000 1.000 .712 
High Basophils – Abs 
(Diff) 
1.000 1.000 .712 
High Basophils - Rel 
(Diff) 
.712 .712 1.000 
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Table 47 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 6 Inflammation B 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.315 .927 3 
 
Table 48 
Inter-Item Correlation Matrix for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 7 Electrolyte Kidney Injury 
 
 Carbon Dioxide Low CO2 
Anion 
Gap 
Carbon Dioxide 1.000 1.000 -.160 
Low CO2 1.000 1.000 -.160 
Anion Gap -.160 -.160 1.000 
 
Table 49 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 7 Electrolyte Kidney 
Injury 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.587 .468 3 
 
Table 50 
Inter-Item Correlation Matrix for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 8 Hemoglobin Kidney Injury  
 
 
High 
Mean_Corpuscular_ 
Hemoglobin 
Low 
Mean_Corpuscular
_ Hemoglobin 
High Mean_Corpuscular_ 
Hemoglobin 
1.000 1.000 
Low Mean_Corpuscular- 
Hemoglobin 
1.000 1.000 
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Table 51 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 8 Hemoglobin Kidney Injury 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
1.000 1.000 2 
 
Table 52 
Inter-Item Correlation Matrix for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 9 Incidental Hypertension 
 
 Low WBC_Count High WBC_Count High Platelet_Count 
Low WBC_Count 1.000 1.000 .378 
High WBC_Count 1.000 1.000 .378 
High Platelet_Count .378 .378 1.000 
 
Table 53 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation  
Group 2 Factor 9 Incidental Hypertension 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.089 .809 3 
 
Table 54 
Inter-Item Correlation Matrix for Cases with Normal to High Systolic Blood Pressure at 
Presentation  
Group 2 Factor 10 Severity 
 
 SBP DBP Co-morbidity 
Preadmit_Thiazide_
Diuretic Ethnicity 
SBP 1.000 .637 .264 .126 -.245 
DBP .637 1.000 .221 .101 -.276 
Co-morbidity .264 .221 1.000 -.004 -.219 
Preadmit_Thiazide_
Diuretic 
.126 .101 -.004 1.000 -.103 
Ethnicity -.245 -.276 -.219 -.103 1.000 
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Table 55 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation  
Group 2 Factor 10 Severity 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.441 .209 5 
 
Table 56 
Inter-Item Correlation Matrix for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 11 RAAS Activation 
 
 Potassium High Potassium 
Potassium 1.000 1.000 
High Potassium 1.000 1.000 
 
Table 57 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation  
Group 2 Factor 11 RAAS Activation 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
1.000 1.000 2 
 
Table 58 
Inter-Item Correlation Matrix for Cases with Normal to High Systolic Blood Pressure at 
Presentation  
Group 2 Factor 12 Severity Treatment 
Is 
 Discharge_ARB Admit_ARB 
Discharge_ARB 1.000 .943 
Admit_ARB .943 1.000 
Table 59 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation  
Group 2 Factor 12 Severity Treatment 
 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.970 .970 2 
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Table 60 
Inter-Item Correlation Matrix for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 13 Patient Characteristics 
 
 Gender Age 
Pain Score (Category 
List) 
Gender 1.000 -.108 .047 
Age -.108 1.000 -.256 
Pain Score (Category 
List) 
.047 -.256 1.000 
 
Table 61 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation  
Group 2 Factor 13 Patient Characteristics 
 
 
Cronbach's Alphaa 
Cronbach's Alpha Based on 
Standardized Items N of Items 
-.208 -.402 3 
Note:  aThe value is negative due to a negative average covariance 
among items. This violates reliability model assumptions. 
 
Table 62 
Inter-Item Correlation Matrix for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 14 Blood Pressure Risk 
 Anion Gap Race 
Anion Gap 1.000 -.168 
Race -.168 1.000 
 
Table 63 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 14 Blood Pressure Risk 
 
Cronbach's Alphaa 
Cronbach's Alpha Based on 
Standardized Items N of Items 
-.236 -.403 2 
Note:  aThe value is negative due to a negative average covariance 
among items. This violates reliability model assumptions. 
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Table 64 
Inter-Item Correlation Matrix for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 15 Diuresis 
 
 RR Preadmit_Thiazide_Diuretic Low ALT (SGPT) 
RR 1.000 -.079 .132 
Preadmit_Thiazide_Diuretic -.079 1.000 -.060 
Low ALT (SGPT) .132 -.060 1.000 
 
Table 65 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 15 Diuresis 
 
 
Cronbach's Alphaa 
Cronbach's Alpha Based on 
Standardized Items N of Items 
-.036 -.007 3 
Note:  aThe value is negative due to a negative average covariance 
among items. This violates reliability model assumptions. 
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Group 3 All Cases with Low SBP at Presentation 
Group 3:  Cases with Low Systolic Blood Pressure at Presentation
 
Figure 8 Scree Plot Cases with Low Systolic Blood Pressure at Presentation 
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Table 66 
Total Variance Explained for Cases with Low Systolic Blood Pressure at Presentation 
 
Component 
Rotation Sums of Squared Loadings 
Total % of Variance Cumulative % 
1 5.654 12.564 12.564 
2 3.781 8.402 20.966 
3 3.769 8.375 29.341 
4 3.261 7.246 36.587 
5 2.669 5.931 42.518 
6 2.449 5.443 47.962 
7 2.428 5.396 53.358 
8 2.257 5.017 58.374 
9 2.127 4.726 63.101 
10 2.039 4.530 67.631 
11 2.028 4.508 72.139 
12 1.868 4.151 76.290 
13 1.818 4.040 80.330 
14 1.427 3.171 83.501 
15 1.127 2.504 86.005 
Extraction Method: Principal Component Analysis. 
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Table 67 
Rotated Component Matrix for Cases with Low Systolic Blood Pressure at Presentation 
 
 
Component 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Low Hemotocrit .977               
High Hemotocrit .977               
HgB .960               
Low Hemoglobin .960               
High RBC_Count .914               
Low RBC_Count .914               
Creatinine  .912              
Low Creatinine  .912              
Low BUN  .895              
BUN  .895              
High Magnesium  .545              
High  Eosinophils 
- Rel (Diff) 
  .966             
Low Eosinophils 
- Rel (Diff) 
  .966             
Low Eosinophils, 
Absolute 
  .963             
High Eosinophils, 
Absolute 
  .963             
Low PT    .975            
High PT    .975            
Low INR    .967            
High PTT    .554            
High Basophils – 
Abs (Diff) 
    .961           
Low Basophils – 
Abs (Diff) 
    .961           
High Basophils - 
Rel (Diff) 
    .856           
Low 
Mean_Corpuscul
ar_ Hemoglobin 
     .977          
High 
Mean_Corpusula
r_ Hemoglobin 
     .977          
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Component 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
       .937         
LVEDd       .750         
Calcium        .950        
Low Calcium        .950        
Low Albumin        .535        
Low CO2         .965       
Carbon Dioxide         .965       
Low 
Platelet_Count 
         .970      
High 
Platelet_Count 
         .970      
High Sodium           .989     
Low Sodium           .989     
SBP            .857    
DBP            .825    
Co-morbidity             .751   
SYNCOPY             .710   
Readmission_12 
Mos 
            .634   
LOS              .846  
loop diuretic              .690  
Anion Gap               .800 
Race 
              
-
.519 
Extraction Method: Principal Component Analysis.  
 Rotation Method: Varimax with Kaiser Normalization. 
a. Rotation converged in 7 iterations. 
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Table 68 
Inter-Item Correlation Matrix for Cases with Low Systolic Blood Pressure at 
Presentation 
Group 3 Factor 1 Anemia 
 
 
Low  
Hemotocrit 
High 
Hemotocrit HgB 
Low  
Hemoglobin 
High 
RBC_ 
Count 
Low 
RBC_Count 
Low  
Hemotocrit 
1.000 1.000 .987 .987 .864 .864 
High  
Hemotocrit 
1.000 1.000 .987 .987 .864 .864 
HgB 
.987 .987 
1.00
0 
1.000 .817 .817 
Low  
Hemoglobin 
.987 .987 
1.00
0 
1.000 .817 .817 
High  
RBC_Count 
.864 .864 .817 .817 
1.00
0 
1.000 
Low  
RBC_Count 
.864 .864 .817 .817 
1.00
0 
1.000 
 
Table 69 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation  
Group 1 Factor 1 Anemia 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.872 .984 6 
 
Table 70 
Inter-Item Correlation Matrix for Cases with Low Systolic Blood Pressure at 
Presentation  
Group 3 Factor 2 Kidney Injury 
  
 Low  Creatinine Creatinine Low BUN High Magnesium 
Low  Creatinine 1.000 1.000 .754 .327 
Creatinine 1.000 1.000 .754 .327 
Low BUN .754 .754 1.000 .505 
High Magnesium .327 .327 .505 1.000 
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Table 71 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation  
Group 1 Factor 2 Kidney Injury 
 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.199 .863 4 
 
Table 72 
Inter-Item Correlation Matrix for Cases with Low Systolic Blood Pressure at 
Presentation  
Group 3 Factor 3 Heart Injury Lab Predictor  
 
 
High  
Eosinophils - 
Rel (Diff) 
High  
Eosinophils, 
Absolute 
Low  
Eosinophils - 
Rel (Diff) 
Low 
Eosinophils, 
Absolute 
High  Eosinophils 
- Rel (Diff) 
1.000 .870 1.000 .870 
High  Eosinophils, 
Absolute 
.870 1.000 .870 1.000 
Low Eosinophils - 
Rel (Diff) 
1.000 .870 1.000 .870 
Low Eosinophils, 
Absolute 
.870 1.000 .870 1.000 
 
Table 73 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation  
Group 1 Factor 3 Heart Injury Lab Predictor 
 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.754 .977 4 
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Table 74 
Inter-Item Correlation Matrix for Cases with Low Systolic Blood Pressure at 
Presentation  
Group 3 Factor 4 Coagulopathy  
 
 Low PT High PT High PTT Low INR 
Low PT 1.000 1.000 .403 .987 
High PT 1.000 1.000 .403 .987 
High PTT .403 .403 1.000 .384 
Low INR .987 .987 .384 1.000 
 
Table 75 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation  
Group 1 Factor 4 Coagulopathy 
 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.682 .901 4 
 
Table 76 
Inter-Item Correlation Matrix for Cases with Low Systolic Blood Pressure at 
Presentation 
Group 3 Factor 5 Inflammation B  
 
 
High Basophils - Abs 
(Diff) 
Low Basophils – 
Abs (Diff) 
High Basophils - 
Rel (Diff) 
High Basophils – Abs 
(Diff) 
1.000 1.000 .712 
Low Basophils – Abs 
(Diff) 
1.000 1.000 .712 
High Basophils - Rel 
(Diff) 
.712 .712 1.000 
 
Table 77 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 1 Factor 5 Inflammation B 
 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.315 .927 3 
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Table 78 
Inter-Item Correlation Matrix for Cases with Low Systolic Blood Pressure at 
Presentation 
Group 3 Factor 6 Hemoglobin Kidney Injury  
 
 
High Mean_Corpuscular_ 
Hemoglobin 
Low Mean_Corpuscular _ 
Hemoglobin 
High Mean_Corpuscular_ 
Hemoglobin 
1.000 1.000 
Low Mean_Corpuscular_ 
Hemoglobin 
1.000 1.000 
 
Table 79 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 1 Factor 6 Hemoglobin Kidney Injury  
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
1.000 1.000 2 
 
Table 80 
Inter-Item Correlation Matrix for Cases with Low Systolic Blood Pressure at 
Presentation 
Group 3 Factor 7 Heart Injury  
 
 High Troponin I Tropinin LVEDd 
High Troponin I 1.000 .999 .558 
Tropinin .999 1.000 .559 
LVEDd .558 .559 1.000 
 
Table 81 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 1 Factor 7 Heart Injury 
 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.069 .878 3 
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Table 82 
Inter-Item Correlation Matrix for Cases with Low Systolic Blood Pressure at 
Presentation 
Group 3 Factor 8 Calcium-Albumin Complex  
 
 Calcium Low Calcium Low Albumin 
Calcium 1.000 1.000 .461 
Low Calcium 1.000 1.000 .461 
Low Albumin .461 .461 1.000 
 
Table 83 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 1 Factor 8 Calcium-Albumin Complex  
 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.847 .842 3 
 
Table 84 
Inter-Item Correlation Matrix for Cases with Low Systolic Blood Pressure at 
Presentation 
Group 3 Factor 9 Electrolyte Imbalance 
 
 Low CO2 Carbon Dioxide 
Low CO2 1.000 1.000 
Carbon Dioxide 1.000 1.000 
 
Table 85 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 3 Factor 9 Electrolyte Imbalance  
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
1.000 1.000 2 
 
  
DEVELOPMENT OF THE RISK MODEL FOR RESIDENT TRAINING 87 
 
 
 
Table 86 
Inter-Item Correlation Matrix for Cases with Low Systolic Blood Pressure at 
Presentation 
Group 3 Factor 10 Platelet Activation 
 
 High Platelet_Count Low Platelet_Count 
High Platelet_Count 1.000 1.000 
Low Platelet_Count 1.000 1.000 
 
Table 87 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 3 Factor 10 Platelet Activation 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
1.000 1.000 2 
 
Table 88 
Inter-Item Correlation Matrix for Cases with Low Systolic Blood Pressure at 
Presentation 
Group 3 All Factor 11 Natremia  
 
 High Sodium Low Sodium 
High Sodium 1.000 1.000 
Low Sodium 1.000 1.000 
 
Table 89 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 3 Factor 11 Natremia 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
1.000 1.000 2 
 
Table 90 
Inter-Item Correlation Matrix for Cases with Low Systolic Blood Pressure at 
Presentation 
Group 3 Factor 12 Blood Pressure Measurement 
 
 SBP DBP 
SBP 1.000 .637 
DBP .637 1.000 
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Table 91 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 3 Factor 12 Blood Pressure Measurement 
 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.761 .778 2 
 
Table 92 
Inter-Item Correlation Matrix for Cases with Low Systolic Blood Pressure at 
Presentation 
Group 3 Factor 13 Severity 
 
 Co-morbidity Syncopy Readmission_12 Mos 
Co-morbidity 1.000 .337 .423 
Syncopy .337 1.000 .183 
Readmission_12 Mos .423 .183 1.000 
 
Table 93 
Reliability Statistics for Cases with Low Systolic Blood Pressure At Presentation 
Group 3 Factor 13 Severity 
 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.288 .579 3 
 
Table 94 
Inter-Item Correlation Matrix for Cases with Low Systolic Blood Pressure at 
Presentation 
Group 3 Factor 14 Treatment 
 
 LOS loop diuretic 
LOS 1.000 .353 
loop diuretic .353 1.000 
 
Table 95 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 3 Factor 14 Treatment 
 
Cronbach's Alpha 
Cronbach's Alpha Based on 
Standardized Items N of Items 
.015 .522 2 
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Table 96 
Inter-Item Correlation Matrix for Cases with Low Systolic Blood Pressure at 
Presentation 
Group 3 Factor 15 Blood Pressure Risk 
 
 Anion Gap Race 
Anion Gap 1.000 -.168 
Race -.168 1.000 
 
Table 97 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 3 Factor 15 Blood Pressure Risk 
 
 
Cronbach's Alphaa 
Cronbach's Alpha Based on 
Standardized Items N of Items 
-.236 -.403 2 
Note: aThe value is negative due to a negative average covariance 
among items.  This violates reliability assumptions.  
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Table 98 
Factors Derived from Each Group for the First Analysis 
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ICD/CRT
SBP Factor
All Factor (1-3) 1 2 3
a
Normal/High Factor (1-9) 5 6 3 1
b
9 8 2 4 7
Low Factor (1-9) 1 4 3 7 6 2 5 8 9
c
a
Inflammation B cormoditity, tobacco use and inflammation consisting of laboratory value for high basophils, low eosinphils and measure of left ventricular diastolic diameter (LVEDd).
b Coagulopathy Factor was found in previous analyses as significant, a weak α of .136 was found.
c Electrolyte Kidney Injury Factor formed from carbon dioxide and LOS found in other factors exhibited a weak α of .136 was found.
DEVELOPMENT OF THE RISK MODEL FOR RESIDENT TRAINING 91 
 
 
 
Second Analysis 
Table 99 
Group 1:  KMO and Bartlett’s Test for All Cases Regardless of Systolic Blood Pressure 
at Presentation 
Second Analysis 
 
Kaiser-Meyer-Olkin Measure of Sampling 
Adequacy. 
.607 
Bartlett's Test of 
Sphericity 
Approx. Chi-Square 1598.70
9 
Df 28 
Sig. .000 
  
Figure 9 Scree Plot of All Cases Regardless of Systolic Blood Pressure at Presentation  
Second Analysis 
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Table 100 
Second Analysis for Total Variance Explained for All Cases Regardless of Systolic 
Blood Pressure at Presentation 
Second Analysis 
 
 
Component 
Extraction Sums of Squared 
Loadings 
Rotation Sums of Squared 
Loadings 
Total 
% of 
Variance 
Cumulative 
% Total 
% of 
Variance 
Cumulative 
% 
1 2.818 35.229 35.229 2.786 34.827 34.827 
2 1.239 15.489 50.718 1.264 15.801 50.628 
3 1.095 13.689 64.407 1.102 13.779 64.407 
Extraction Method: Principal Component Analysis. 
 
Table 101 
Rotated Component Matrix for All Cases Regardless of Systolic Blood Pressure at 
Presentation  
Second Analysis 
 
Component 
1 2 3 
Low Hemotocrit .988   
HgB .972   
High RBC_Count .922   
Co-morbidity  .790  
Tobacco_Abuse  .769  
High Basophils - Rel (Diff)   .690 
Low Eosinophils - Rel (Diff)   .558 
LVEDd   .558 
Note: Extraction Method: Principal Component Analysis.  Rotation Method: Varimax with Kaiser Normalization.a 
a. Rotation converged in 4 iterations. 
 
Table 102 
Group 1 Factor 1 for Inter-Item Correlation Matrix for All Cases Regardless of Systolic 
Blood Pressure at Presentation  
Second Analysis 
 High Hemotocrit HgB High RBC_Count 
High Hemotocrit 1.000 .987 .864 
HgB .987 1.000 .817 
High RBC_Count .864 .817 1.000 
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Table 103 
Reliability Statistics for All Cases Regardless of Systolic Blood Pressure at Presentation 
Group 1 Factor 1 Anemia  
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha Based 
on Standardized Items 
N of 
Items 
.680 .960 3 
 
Table 104 
Group 1 Factor 1 for Inter-Item Correlation Matrix for All Cases Regardless of Systolic 
Blood Pressure at Presentation  
Group 1 Factor 2 Abuse 
Second Analysis  
 Co-morbidity Tobacco_Abuse 
Co-morbidity 1.000 .251 
Tobacco_Abuse .251 1.000 
 
Table 105 
Reliability Statistics for All Cases Regardless of Systolic Blood Pressure at Presentation 
Group 1 Factor 2 Abuse  
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha Based 
on Standardized Items 
N of 
Items 
.396 .401 2 
 
Table 106 
Group 1 Factor 3 for Inter-Item Correlation Matrix for All Cases Regardless of Systolic 
Blood Pressure at Presentation  
Second Analysis  
 
High Basophils - 
Rel (Diff) 
Low Eosinophils - 
Rel (Diff) LVEDd 
High Basophils - Rel 
(Diff) 
1.000 .059 .061 
Low Eosinophils - Rel 
(Diff) 
.059 1.000 .029 
LVEDd .061 .029 1.000 
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Table 107 
Reliability Statistics for All Cases Regardless of Systolic Blood Pressure at Presentation 
Group 1 Factor 3 Inflammation 
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha Based 
on Standardized Items 
N of 
Items 
.024 .136 3 
 
Table 108 
Group 2:  Cases with Normal to High Systolic Blood Pressure at Presentation 
 
 
Kaiser-Meyer-Olkin Measure of Sampling 
Adequacy. 
.471 
Bartlett's Test of 
Sphericity 
Approx. Chi-Square 2388.33
5 
Df 351 
Sig. .000 
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Figure 10 Scree Plot of Cases with Normal to High Systolic Blood Pressure at 
Presentation 
  
DEVELOPMENT OF THE RISK MODEL FOR RESIDENT TRAINING 96 
 
 
 
Table 109 
Total Variance Explained for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Component 
Extraction Sums of Squared 
Loadings 
Rotation Sums of Squared 
Loadings 
Total 
% of 
Variance 
Cumulative 
% Total 
% of 
Variance 
Cumulative 
% 
1 2.664 9.868 9.868 2.329 8.625 8.625 
2 2.478 9.179 19.047 2.224 8.238 16.862 
3 2.339 8.662 27.709 2.120 7.851 24.713 
4 2.123 7.863 35.572 2.022 7.488 32.201 
5 1.938 7.179 42.751 1.966 7.280 39.481 
6 1.897 7.026 49.776 1.956 7.246 46.727 
7 1.840 6.814 56.590 1.908 7.066 53.793 
8 1.600 5.924 62.515 1.761 6.523 60.315 
9 1.295 4.798 67.312 1.606 5.949 66.265 
10 1.213 4.493 71.805 1.323 4.900 71.165 
11 1.036 3.835 75.641 1.208 4.476 75.641 
Note: Extraction Method: Principal Component Analysis. 
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Table110 
Rotated Component Matrix for Total Variance Explained for Cases with Normal to 
High Systolic Blood Pressure at Presentation 
 
Component 
1 2 3 4 5 6 7 8 9 10 
11         
12 
High PT .953           
Low INR .947           
High PTT .605           
High 
WBC_Count 
 .958          
Low Neutrophils 
- Abs(Diff) 
 .932          
Low Monocytes - 
Abs(Diff) 
 .545          
Bun   .876         
Creatinine   .826         
Mag   .707         
Abnormal_Labs    .760        
CV    .730        
SBP    .708        
Discharge_HTN    .515        
Discharge_ARB     .977       
Admit_ARB     .976       
High RBC_Count     .954      
High Hemotocrit      .922      
High Eosinophils, 
Absolute 
      .962     
High Eosinophils 
- Rel (Diff) 
      .958     
DEVELOPMENT OF THE RISK MODEL FOR RESIDENT TRAINING 98 
 
 
 
High Basophils - 
Rel (Diff) 
       .919    
Component 
 
1 2 3 4 5 6 768 9 10 11 
         
12 
High Basophils - 
Abs (Diff) 
       .902    
LVEDd         .883   
High Troponin I         .858   
Highmean_Corp
uscular_ 
Hemoglobin 
         .850  
Low Albumin          .506  
Carbon Dioxide           .680 
High Sodium           .618 
Extraction Method: Principal Component Analysis.  
 Rotation Method: Varimax with Kaiser Normalization. (converged in 7 iterations) 
 
Table 111 
Group 2 Factor 1 for Inter-Item Correlation Matrix for Cases with Normal to High 
Systolic Blood Pressure at PresentationSecond Analysis  
 High PT Low INR High PTT 
High PT 1.000 .987 .403 
Low INR .987 1.000 .384 
High PTT .403 .384 1.000 
 
Table 112 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 1 Coagulopathy 
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.024 .136 3 
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Table 113 
Group 2 Factor 2 Inter-Item Correlation Matrix for C Cases with Normal to High Systolic 
Blood Pressure at Presentation 
Second Analysis 
 
High 
WBC_Count 
Low NEUTROPHILS 
– Abs (Diff) 
Low 
MONOCYTES – 
Abs (Diff) 
High WBC_Count 1.000 .964 .341 
Low Neutrophils – Abs 
(Diff) 
.964 1.000 .255 
Low Monocytes – Abs 
(Diff) 
.341 .255 1.000 
 
Table 114 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 2 Incidental Hypertension 
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.458 .813 3 
 
Table 115 
Group 2 Factor 3 for Inter-Item Correlation Matrix for Cases with Normal to High 
Systolic Blood Pressure at Presentation 
Second Analysis  
 BUN Creatinine Mag 
BUN 1.000 .754 .505 
Creatinine .754 1.000 .327 
Mag .505 .327 1.000 
 
  
DEVELOPMENT OF THE RISK MODEL FOR RESIDENT TRAINING 100 
 
 
 
Table 116 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 3 Kidney Injury 
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.128 .771 3 
 
Table 117 
Group 2 Factor 4 for Inter-Item Correlation Matrix for Cases with Normal to High 
Systolic Blood Pressure at Presentation 
Second Analysis 
 Abnormal_:Labs CV SBP Discharge_HTN 
Abnormal_Labs 1.000 .481 .376 .220 
CV .481 1.000 .369 .193 
SBP .376 .369 1.000 .209 
Discharge_HTN .220 .193 .209 1.000 
 
Table 118 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 4 Severity 
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.069 .640 4 
 
Table 119 
Group 2 Factor 5 for Inter-Item Correlation Matrix for Cases with Normal to High 
Systolic Blood Pressure at Presentation 
Second Analysis 
 Discharge_ARB Admit_ARB 
Discharge_ARB 1.000 .943 
Admit_ARB .943 1.000 
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Table 120 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 5 Severity Treatment 
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.970 .970 2 
 
Table 121 
Group 2 Factor 6 for Inter-Item Correlation Matrix for Cases with Normal to High 
Systolic Blood Pressure at Presentation 
Second Analysis 
 High RBC_Count High Hemotocrit 
High RBC_Count 1.000 .864 
High Hemotocrit .864 1.000 
 
Table 122 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 6 Anemia 
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.342 .927 2 
 
Table 123 
Group 2 Factor 7 for Inter-Item Correlation Matrix for Cases with Normal to High 
Systolic Blood Pressure at Presentation 
Second Analysis 
 
High Eosinophils, 
Absolute 
High Eosinophils - Rel 
(Diff) 
High Eosinophils, 
Absolute 
1.000 .870 
High Eosinophils - 
Rel (Diff) 
.870 1.000 
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Table 124 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 7 Heart Injury Lab Predictor 
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.263 .930 2 
 
Table 125 
Group 2 Factor 8 for Inter-Item Correlation Matrix for Cases with Normal to High 
Systolic Blood Pressure at Presentation 
Second Analysis 
 
High Basophils - 
Abs (Diff) 
High Basophils - 
Rel (Diff) 
High Basophils – Abs 
(Diff) 
1.000 .712 
High Basophils - Rel 
(Diff) 
.712 1.000 
 
Table 126 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 8 Inflammation B 
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.224 .832 2 
 
Table 127 
Group 2 Factor 9 for Inter-Item Correlation Matrix for Cases with Normal to High 
Systolic Blood Pressure at Presentation 
Second Analysis 
 LVEDd High Troponin I 
LVEDd 1.000 .558 
High Troponin I .558 1.000 
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Table 128 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor 9 Heart Injury 
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.046 .717 2 
 
Table 129 
Group 2 Factor 10 for Inter-Item Correlation Matrix for Cases with Normal to High 
Systolic Blood Pressure at Presentation  
Second Analysis 
 
High Mean_Corpuscular_ 
Hemoglobin Low Albumin 
High Mean_Corpuscular_ 
Hemoglobin 
1.000 .214 
Low Albumin .214 1.000 
 
Table 130 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 1 Factor 10 Hemoglobin Kidney Injury 
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.138 .353 2 
 
Table 131 
Group 2 Factor 11 for Inter-Item Correlation Matrix for Cases with Normal to High 
Systolic Blood Pressure at Presentation 
Second Analysis 
 Carbon Dioxide High Sodium 
Carbon Dioxide 1.000 .071 
High Sodium .071 1.000 
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Table 132 
Reliability Statistics for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
Group 2 Factor11 Electrolyte Kidney Injury 
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.263 .930 2 
 
3:  Cases with Low Systolic Blood Pressure at Presentation 
Table 133 
KMO and Bartlett’s Test for Cases with Normal to High Systolic Blood Pressure at 
Presentation 
 
Kaiser-Meyer-Olkin Measure of Sampling 
Adequacy. 
.568 
Bartlett's Test of 
Sphericity 
Approx. Chi-Square 1491.29
4 
Df 231 
Sig. .000 
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Figure 11 Scree Plot of Cases with Low Systolic Blood Pressure at Presentation 
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Table 134 
Total Variance Explained for Cases with Low Systolic Blood Pressure at Presentation 
Component 
Extraction Sums of Squared 
Loadings 
Rotation Sums of Squared 
Loadings 
Total 
% of 
Variance 
Cumulati
ve % Total 
% of 
Variance 
Cumulative 
% 
1 3.260 14.819 14.819 2.855 12.979 12.979 
2 2.685 12.206 27.025 2.376 10.801 23.780 
3 2.023 9.194 36.219 2.155 9.796 33.576 
4 1.904 8.654 44.872 1.899 8.633 42.210 
5 1.766 8.027 52.899 1.739 7.904 50.114 
6 1.415 6.431 59.330 1.592 7.236 57.350 
7 1.378 6.264 65.593 1.458 6.627 63.977 
8 1.126 5.117 70.710 1.399 6.358 70.335 
9 1.074 4.881 75.591 1.156 5.256 75.591 
 
Extraction Method: Principal Component Analysis. 
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Table 135 
Rotated Component Matrix for Cases with Low Systolic Blood 
Pressure at Presentation 
 
Component 
1 2 3 4 5 6 7 8 9 
High Hemotocrit .973         
HgB .956         
High RBC_Count .915         
Abnormal_Labs  .791        
CV  .766        
Co-morbidity  .744        
Readmission_12 Mos  .742        
BUN   .878       
Creatinine   .846       
High Magnesium   .641       
High  Eosinophils - 
Rel (Diff) 
   .966      
High  Eosinophils, 
Absolute 
   .954      
High Basophils – Abs 
(Diff) 
    .927     
High Basophils - Rel 
(Diff) 
    .907     
LVEDd      .879    
High Troponin I      .866    
High PT       .829   
High PTT       .811   
Low Albumin        .808  
Calcium        .792  
LOS         .688 
Carbon Dioxide         .673 
Extraction Method: Principal Component Analysis.  
 Rotation Method: Varimax with Kaiser Normalization.a 
a. Rotation converged in 6 iterations. 
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Table 136 
Group 3 Factor 1 for Inter-Item Correlation Matrix for Cases with Low Systolic Blood 
Pressure at Presentation 
Second Analysis 
 
 High Hemotocrit HgB High RBC_Count 
High Hemotocrit 1.000 .987 .864 
HgB .987 1.000 .817 
High RBC_Count .864 .817 1.000 
 
Table 13 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 3 Factor 1 Anemia 
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.263 .930 2 
 
Table 138 
Group 3 Factor 2 for Inter-Item Correlation Matrix for Cases with Low Systolic Blood 
Pressure at Presentation 
Second Analysis 
 Abnormal_Labs CV 
Co-
morbidity 
Readmission_12 
Mos 
Abnormal_Labs 1.000 .483 .443 .459 
CV .483 1.000 .436 .439 
Co-morbidity .443 .436 1.000 .423 
Readmission_12 
Mos 
.459 .439 .423 1.000 
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Table 139 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 3 Factor 2 Severity 
Second Analysis   
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.595 .764 4 
 
Table 140 
Group 3 Factor 3 for Inter-Item Correlation Matrix for Cases with Low Systolic Blood 
Pressure at Presentation 
Second Analysis 
 BUN High Magnesium 
High Eosinophils - 
Rel (Diff) 
BUN 1.000 .505 .036 
High Magnesium .505 1.000 .107 
High Eosinophils - Rel (Diff) .036 .107 1.000 
 
Table 141 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 3 Factor 3 Kidney Injury 
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.034 .453 3 
 
Table 142 
Group 3 Factor 4 for Inter-Item Correlation Matrix for Cases with Low Systolic Blood 
Pressure at Presentation 
Second Analysis 
 
High Eosinophils - 
Rel (Diff) 
High Eosinophils, 
Absolute 
High Eosinophils - Rel (Diff) 1.000 .870 
High Eosinophils, Absolute .870 1.000 
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Table 143 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 3 Factor 4 Heart Injury Lab Predictor 
Second Analysis  
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.263 .930 2 
 
Table 144 
Group 3 Factor 5 for Inter-Item Correlation Matrix for Cases with Low Systolic Blood 
Pressure at Presentation 
Second Analysis 
 
High Basophils - 
Abs (Diff) 
High Basophils - Rel 
(Diff) 
High Basophils - Abs 
(Diff) 
1.000 .712 
High Basophils - Rel 
(Diff) 
.712 1.000 
 
Table 145 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 3 Factor 5 Inflammation B 
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.224 .832 2 
 
Table 146 
Group 3 Factor 6 for Inter-Item Correlation Matrix for Cases with Low Systolic Blood 
Pressure at Presentation 
Second Analysis 
 LVEDd High Troponin I 
LVEDd 1.000 .558 
High Troponin I .558 1.000 
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Table 147 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 3 Factor 6 Heart Injury 
Second Analysis 
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.046 .717 2 
 
Table 148 
Group 3 Factor 7 for Inter-Item Correlation Matrix for Cases with Low Systolic Blood 
Pressure at Presentation 
Second Analysis 
 High PT High PTT 
High PT 1.000 .403 
High PTT .403 1.000 
 
Table 149 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 3 Factor 7 Coagulopathy 
Second Analysis  
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.504 .575 2 
 
Table 150 
Group 3 Factor 8 for Inter-Item Correlation Matrix for Cases with Low Systolic Blood 
Pressure at Presentation 
Second Analysis 
 Low Albumin Calcium 
Low Albumin 1.000 .461 
Calcium .461 1.000 
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Table 151 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 3 Factor 8 Albumin-Calcium Complex 
Second Analysis  
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.630 .631 2 
 
Table 152 
Group 3 Factor 9 for Inter-Item Correlation Matrix for Cases with Low Systolic Blood 
Pressure at Presentation 
Second Analysis 
 LOS Carbon Dioxide 
LOS 1.000 .057 
Carbon Dioxide .057 1.000 
 
Table 153 
Reliability Statistics for Cases with Low Systolic Blood Pressure at Presentation 
Group 3 Factor 9 Electrolyte Kidney Injury 
Second Analysis  
Cronbach's 
Alpha 
Cronbach's Alpha 
Based on Standardized 
Items 
N of 
Items 
.107 .108 2 
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Findings 
After the study site’s Crystal Report approval was granted by the Helios 
Administrative Group, data were obtained from discreet fields identified in Epic.  
Because Epic was recently installed, all of the elements identified required investigation 
by the principal performance management analyst in the Operational Analytics 
department at the study site.  Some variables were stored in notes that are not easily 
queryable because the report was stored as an Adobe pdf file imported from other 
software programs such as Syngo, a Siemens imaging software.  The major challenge 
for accessing patients coming to the emergency room was the electronic medical record 
change from EMStat®, a system that was well mature and robust with many of the data 
elements laid out, to the new system, EPIC where the data elements had to found and 
validated for accuracy.  All cases for patients admitted for decompensated heart failure 
(ICD 428.xx) for the 2014 year were selected.  All cases were screened for entry criteria 
and the first 300 chronologically dated cases were identified. 
EFA was conducted on the data abstracted from 300 electronic medical records 
stored in EPIC software and entered in an Excel spreadsheet.  Patient inclusion was 
limited to those patients with decompensated heart requiring intravenous diuretic 
treatment.  Data were abstracted via report analysis by the IT administrator and missing 
variables were manually abstracted by the author.  All factors were reviewed by the 
Program Director of Advanced Heart Failure and Transplantation at the study site, for 
clinical meaningfulness. 
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Initial Analysis 
Group 1 All Cases Regardless of SBP at Presentation 
EFA conducted on cases regardless of SBP at presentation resulted in fourteen 
factors with explaining 87.292% of the variance (Table 6).  Fourteen factors were also 
resulted in the Cattell scree test which plots the components on the X axis and the 
corresponding eigenvalues as the Y-axis (Figure 6). Reliability indices for each factor 
were high (i.e., > 0.7) as measured by Cronbach Alpha (α) (Tables 9, 11, 13, 15, 17, 19, 
21, 23, 25, 27, 29, 31, and 33), a measure of internal consistency reliability, except for 
factor 8 with α=0.687 (Table 23) and factor 9 with α=0.628 (Table 25).  Tables 8, 10, 12, 
14, 16, 18, 20, 22, 24, 26, 28, 30, and 32 indicate correlation of each item with the sum 
of all remaining items in a matrix (Inter-Item Correlation Matrix for All Cases Regardless 
of Systolic Blood Pressure at Presentation).  Factors derived from this initial analysis of 
all cases regardless of SBP at presentation were evaluated and named based on 
clinical criteria.  The factor names were carried throughout the remaining analyses and 
new factors were named with each analysis. 
Factor 1 named Anemia consists of laboratory values for high and low 
hemotocrit, hemoglobin and low hemoglobin, and high and low red blood cells (RBC) 
Count.  Factor 2 named Heart Injury Lab Predictor consists of laboratory values for high 
and low relative and absolute eosinophils.  Factor 3 named Coagulopathy consists of 
laboratory values for high and low prothrombin time (PT), partial thromboplastin time 
(PTT) and international normalized ratio (INR).  Factor 4 name Severity consists of 
SBP, grouping of abnormal laboratory results, DBP, grouping of co-morbidity, 12 month 
hospital readmission rate, and ethnicity (as defined in the site’s electronic medical 
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record).  Factor 5 named Hemoglobin Kidney Injury consists of laboratory values for 
high and low mean corpuscular hemoglobin.  Factor 6 named Heart Injury consists of 
laboratory values for troponin and high troponin and echocardiogram measure of left 
ventricular diastolic diameter (LVEDd).  Factor 7 named Electrolyte Kidney Injury 
consists of laboratory values for carbon dioxide and low carbon dioxide.  Factor 8 
named Inflammation B consists of laboratory values for high and low basophils.  Factor 
9 named Incidental Hypertension consists of laboratory values for high and low white 
blood Count (WBC).  Factor 10 named Natremia consists of laboratory values for high 
and low sodium.  Factor 11 named Inflammation B consists of laboratory values for high 
and low absolute lymphocytes.  Factor 12 named Kidney Injury consists of laboratory 
values for creatinine and low creatinine.  Factor 13 named Abuse consists of abuse of 
current or past illicit drug, alcohol or tobacco use. 
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Group 2 All Cases with Normal to High SBP at Presentation 
EFA conducted on cases with normal to high SBP at presentation resulted in 
fifteen factors with explaining 81.305% of the variance (Table 35).  Fifteen factors were 
also resulted in the Cattell scree test (Figure 7).  Reliability indices for each factor 
resulted in significance as measured by Cronbach α of ≥0.7 (Tables 37, 39, 41, 43, 45, 
47, 49, 51, 53 and 55, except for factor 8 with α =0.689 (Table 51) and factor 13 with α 
=.053 (Table 61).  Tables 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62. and 64 
indicate correlation of each item with the sum of all remaining items in a matrix (Inter-
Item Correlation Matrix for Cases with Normal to High Systolic Blood Pressure at 
Presentation).  The factors derived from the initial analysis of all cases regardless of 
SBP at presentation were all found except for the Severity Factor consisting of group of 
abnormal labs, grouping of comorbidity, 12 month readmission rate and implantable 
cardioverter defibrillator / Cardiac Resynchronization Therapy (ICD/CRT) implant, the 
Heart Injury Factor consisting of laboratory values for troponin, high troponin and 
echocardiogram measurement of left ventricular end diastolic diameter (LVEDd), 
Electrolyte Kidney Injury Factor consisting of laboratory values for low carbon dioxide 
and carbon dioxide, Natremia consisting of laboratory values for high and low sodium, 
Inflammation L consisting of laboratory values for high and low absolute lymphocytes, 
and Abuse consisting of abuse of current or past illicit drug, alcohol or tobacco use.  
Additional factors were revealed and these are Electrolyte Imbalance, Severity, renin-
angiotensin-aldosterone system (RAAS), Severity of Treatment, Patient Characteristics, 
Blood Pressure Risk, and Diuresis. 
  
DEVELOPMENT OF THE RISK MODEL FOR RESIDENT TRAINING 117 
 
 
 
Group 3 All Cases with Low SBP at Presentation 
EFA conducted on cases with low SBP at presentation resulted in fifteen actors 
with explaining 86.005% of the variance (Table 67).  Fifteen factors were also resulted 
in the Cattell scree test (Figure 8).  Reliability indices for each factor resulted in 
significance as measured by Cronbach α of >0.7 (Tables 69, 71, 73, 75, 77, 79, 81, 83, 
85, 87, 91, 93, 95, and 97) except for factor 13 with α = .579 (Table 93), factor 14 with 
α=0.522), and factor 15 with α= -.403 (Table 97).  Cronbach α will be negative 
whenever the sum of the individual item variances is greater than the scale variance 
and can be contributed to a large measurement error, low sample size, reverse coding, 
or variables that do not measure the same factor (as seen with negative covariance).  
Anion gap is related to race and race value obtained was -0.519 (Table 66).  In this 
case, race may be inversely related to anion gap value.  Tables 68, 70, 72, 74, 75, 78, 
80, 82, 84, 86, 88, 90, 92, 94, and 96 indicate correlation of each item with the sum of 
all remaining items in a matrix (Inter-Item Correlation Matrix for Cases with Low Systolic 
Blood Pressure at Presentation).  The factors derived from the initial analysis of all 
cases regardless of SBP at presentation were all found except for Electrolyte Kidney 
Injury Factor consisting of laboratory values for carbon dioxide and high sodium, 
Incidental hypertension Factor consisting of laboratory values for high WBC Count, low 
neutrophils (absolute) and low monocytes (absolute), Inflammation L Factor consisting 
of lab values for high and low lymphocytes, and Abuse Factor consisting of current or 
past illicit drug, alcohol or tobacco use. 
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Second Analysis 
Sampling adequacy was tested with Kaiser-Meyer-Olkin (KMO) Measure of 
Sampling Adequacy.  Bartlett’s Test of Sphericity tests the hypothesis that the 
correlation matrix is an identity matrix indicating uncorrelated variables and is accepted 
if >0.5.  Significance levels less than the alpha value set at 0.05 allows rejection of the 
null hypothesis that the population matrix is an identity matrix.  Rejection of the null 
hypothesis allows one to conclude that there are correlations in the data set appropriate 
for factor analysis. 
Group 1 All Cases Regardless of SBP at Presentation 
EFA conducted on cases regardless of SBP at presentation resulted in three 
factors with explaining 64.407% of the variance Table 100).  Three factors were also 
resulted in the Cattell scree test (Figure 9).  Sampling adequacy was tested with Kaiser-
Meyer-Olkin (KMO) Measure of Sampling Adequacy was 0.607 and Bartlett’s Test of 
Sphericity was significant at 0.000 (Table 99).  Reliability indices for each factor resulted 
in significance as measured by Cronbach α of >0.7 in only Factor 1 (Tables 103, 105 
and 107).  The three factors that resulted were the Anemia Factor consisting of 
laboratory values for low hematocrit, hemoglobin and high red blood cells (RBC) Count, 
Severity consisting of a group of comorbidity and tobacco use, and Inflammation 
consisting of laboratory values for high basophils, low eosinophils and echocardiogram 
measure of left ventricular diastolic diameter (LVEDd).  Tables 102, 104, and 106 
indicate correlation of each item with the sum of all remaining items in a matrix (Inter-
Item Correlation Matrix for All Cases Regardless of Systolic Blood Pressure at 
Presentation).  The variables for inflammation, laboratory values for high basophils and 
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low relative eosinophils, and echo measurement of left ventricular end diastolic diameter 
(LVEDd) in this group differ significantly from other groups in the previous analyses and 
resulted in a poor α of .103. 
Group 2 All Cases with Normal to High SBP at Presentation 
EFA conducted on cases with normal or high SBP at presentation resulted in 
eleven factors with explaining 75.641% of the variance (Table 109)  Sampling adequacy 
was tested with Kaiser-Meyer-Olkin (KMO) Measure of Sampling Adequacy was 0.471 
and Bartlett’s Test of Sphericity was significant at 0.000 (Table 108).  Reliability indices 
for each factor resulted in significance as measured by Cronbach α of >0.7 except for 
the Coagulopathy Factor, the Severity Factor, and the Hemoglobin Kidney Injury Factor 
(Tables 112, 118, and 130, respectively).  The eleven factors that resulted were 
Coagulopathy consists of laboratory values for high and low prothrombin time (PT), 
partial thromboplastin time (PTT) and international normalized ratio (INR), Incidental 
hypertension consisting of laboratory values for high WBC Count, low neutrophils 
(absolute) and low monocytes (absolute), Kidney Injury consisting of laboratory values 
for blood urea nitrogen (BUN), creatinine, and magnesium, Severity consisting of a 
group of abnormal labs, cardiovascular disease, SBP and hypertension at discharge, 
angiotensin II receptor blocker (ARB) treatment consisting of use of angiotensin II 
receptor blocker (ARB) at admission and at discharge, Anemia consisting of laboratory 
values for high red blood cells (RBC) Count and high  Hemotocrit, Heart Injury 
Laboratory Predictory consisting of laboratory values for high  Eosinophils (absolute) 
and high  Eosinophils (relative), Inflammation B consisting of laboratory values for high 
basophils (relative) and high basophils (absolute), Heart Injury consisting of laboratory 
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value for troponin and echocardiogram measure of left ventricular end diastolic diameter 
(LVEDd), Hemoglobin Kidney Injury consisting of laboratory values for high mean 
corpuscular hemoglobin and low albumin, and Electrolyte Kidney Injury consisting of 
laboratory values for carbon dioxide and high sodium. Tables 111, 113, 115, 117, 119, 
121, 123, 125, 127, 129, and 131 indicate correlation of each item with the sum of all 
remaining items in a matrix (Inter-Item Correlation Matrix for Cases with Normal to High 
Systolic Blood Pressure at Presentation).  Although the Coagulopathy Factor was found 
in previous analyses as significant, a weak α of .136 was found. 
Group 3 All Cases with Low SBP at Presentation 
EFA conducted on cases with low SBP at presentation resulted in nine factors 
with explaining 75.591% of the variance (Table 134).  Sampling adequacy was tested 
with Kaiser-Meyer-Olkin (KMO) Measure of Sampling Adequacy was 0.568 and 
Bartlett’s Test of Sphericity was significant at 0.000 (Table 133).  Reliability indices for 
each factor resulted in significance as measured by Cronbach α of >0.7 except for the 
Kidney Injury, Coagulopathy Factor, Albumin-Calcium Factor and Electrolyte Kidney 
Injury Factor (Tables 141, 149, 151, and 153, respectively).  The nine factors that 
resulted were Anemia consisting of laboratory values for high  Hemotocrit, hemoglobin 
and high red blood cells (RBC) Count, Severity consisting of grouping of abnormal labs, 
cardiovascular disease, grouping of co-morbidity and 12 month readmission rate, 
Kidney Injury consisting of laboratory blood urea nitrogen (BUN), creatinine and high 
magnesium, Heart Injury Laboratory Predictor consisting of laboratory values for high  
Eosinophils (relative) and high  Eosinophils (absolute), Inflammatory B for high 
basophils (absolute) and high basophils (relative), Heart Injury consisting of laboratory 
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value for high troponin and echocardiogram measure of left ventricular end diastolic 
diameter (LVEDd).  The variables for inflammation, laboratory values for high basophils 
and low relative eosinophils, and echo measurement of left ventricular end diastolic 
diameter (LVEDd) in this group differ significantly from other groups in the previous 
analyses and resulted in a poor α of .103. Coagulopathy consisting of laboratory values 
with high prothrombin time (PT), high partial thromboplastin time (PTT), Calcium-
Albumin Complex consisting of laboratory values for low albumin and calcium, and 
Treatment consisting of length of stay and laboratory value for carbon dioxide. 
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CHAPTER 5 DISCUSSION 
The purpose of this study was to characterize patients hospitalized with acute 
decompensated heart failure with and without low systolic blood pressure using EFA.  
Direct and surrogate measurements are measured and dictate treatment. Medical 
laboratory results are key in the role in detecting, diagnosis and treatment.  Blood, urine 
and imaging test results help to determine the presence, extent, or absence of disease 
and its effects and monitor the effectiveness of treatment. Although the Mayo Clinic, the  
American Clinical Laboratory Association (an industry organization), and the Center for 
Disease Control and Prevention (CDC) all cite that 70% of treatment decisions are based 
on laboratory test results (http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5413a1.htm; 
https://web.archive.org/web/20070320220017/http://www.clinical-
labs.org/issues/value/index.shtml; 
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5413a1.htm) no original source was 
found after an exhaustive review of the literature.  The earliest reference to this statistic 
was found in an article by the Mayo clinic but no reference was provided (Forsman, 1996). 
Interestingly, this article focused on financial aspects of laboratory testing by managed 
care organizations rather than the source of the finding that laboratory results direct 
clinical decision making.  The writer also consulted the Instruction Services Coordinator 
who is the Liaison Librarian to the College of Education and Department of Anthropology 
at the Wayne State University Library System and no original source was found for this 
widely used statistic.  The discussion and impact of using such a statistic to drive patient 
care and issues with laboratory reporting errors is beyond the scope of this paper (Bonini, 
2002). 
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Safety and cost-effective management is paramount, but there is a deluge of 
clinical data. The question investigated was could the method of data reduction using 
EFA elicit a parsimonious group of factors to summarize the relationship between these 
variables?  A better understanding of the characteristics and outcomes of patients 
presented with acute decompensated heart failure with and without low systolic blood 
pressure could potentially lead to individualized treatment modalities tailored to effectively 
and economically improve care. 
Interpretation of Findings 
The major findings of the study found using EFA were that two factors, Anemia 
and Kidney Function were seen across the three groups.  Group 1 consists of All Cases 
Regardless of SBP at Presentation.  Group 2 consists of All Cases with Normal to High 
SBP at Presentation.  Group 3 consists of All Cases with Low SBP at Presentation.  EFA 
was conducted in a second analysis with the same 3 groups.  The second analysis was 
run since the initial analysis resulted in correlation matrices that were not positive 
definitive.  All variables with linear dependency defined as 1.0 on the inter-item correlation 
matrix when each of the resulting factors were run for a reliability analysis using the alpha 
model were removed.  Variables that loaded on more than one factor, with a factor loading 
less than |.4|, or did not load were removed.  Missing data were replaced with the mean 
which may have contributed to linear dependency.  Again, Group 3, consisting of All 
Cases with Low SBP at Presentation factors were nearly the same as for the other two 
groups.  There were two factors that were not found in Group 3.  One is by definition, 
Incidental Hypertension since this group was defined as presenting with low systolic blood 
pressure.  The other is abuse defined as illicit drug, alcohol or tobacco use.  Group 3 
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cases are patients who are excluded from clinical trial enrollment as described in the 
review of the literature.  However, the resulting factors from this EFA indicate that except 
for hypertension and abuse, the clinical characteristics of patients with low blood pressure 
encountered in the real-world clinical practice do not significantly differ. 
Several individual factors that affect kidney function were also found.  These 
factors include Heart Injury Lab Predictor, Kidney Injury, Coagulopathy, HgB Kidney 
Injury, Incidental HTN and Calcium-Albumin Complex. Anemia and Kidney Function 
factors affect blood pressure.  Anemia decreases blood pressure and inversely, poor 
kidney function increases blood pressure (hypertension).  Low blood pressure is a cause 
of poor kidney function but patients on dialysis were excluded from the study.  As 
discussed in the review of the literature, anemia and kidney function are associated with 
poor outcomes including death in patients admitted with acute decompensated heart 
failure. 
Recommendations for Future Research 
The factors identified in each group using EFA can be tested in a future 
confirmatory factor analysis study.  Once these factors are the confirmed, an Acute 
Decompensated Heart Failure Risk Model can be developed for Emergency Room 
Resident Training within the context of evidence-based medicine.  Over 20 years ago, 
articles appeared describing evidence-based medicine indicating the following: 
A NEW paradigm for medical practice is emerging. Evidence-based 
medicine de-emphasizes intuition, unsystematic clinical experience, and 
pathophysiologic rationale as sufficient grounds for clinical decision 
making and stresses the examination of evidence from clinical research. 
Evidence-based medicine requires new skills of the physician, including 
efficient literature searching and the application of formal rules of evidence 
evaluating the clinical literature. (Guyatt, 1992, p. 2420) 
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However, there is criticism stating, “There are several reasons why the quality of the 
evidence for teaching EBM [evidence-based medicine] is so weak” (Hatala, 2002, 
p.1110).  That is, the evidence for evidenced-based medicine is observational, the 
weakest form of evidence as espoused by the definition of evidence-based medicine.  
The pedagogical approach in medical education where instruction is provided by the 
experienced physician to the novice, namely the medical resident, is in conflict of adult 
learning theory leading to a contributing factor to the success or failure of teaching 
evidence-based medicine.  The shift to student centered learning is based on adult 
learning theory (Spencer, 1999).  Knowles’ (1970) exposure to the term andragogy was 
from, “a Yugoslavian adult educator [Dusan Savicevic] in the mid-sixties and printed in an 
article in Adult Leadership in 1968.” (p. 42).  Andragogy is a Greek word referring to man 
or adult as opposed to a boy in pedagogy.  (andra – meaning man and agogos – meaning 
learning).  Knowles, Holton, and Swanson (2005) reported five underlying assumptions 
in the andragogy model: 
1. The learner is self-directing. Adult learners want to take 
responsibility for their own lives, including the planning, implementing, and 
evaluating of their learning activities. 
2. The learner enters an educational situation with a great deal of 
experience. This experience can be a valuable resource to the learner as 
well as to others. It needs to be valued and used in the learning process. 
3. Adults are ready to learn when they perceive a need to know or do 
something in order to perform more effectively in some aspect of their 
lives. Their readiness to learn may be stimulated by helping them to 
assess the gaps between where they are now and where they want and 
need to be. 
4. Adults are motivated to learn after they experience a need in their 
life situation. For that reason, learning needs to be problem-focused or 
task-centered. Adults want to apply what they have learned as quickly as 
possible. Learning activities need to be clearly relevant to the needs of the 
adult. 
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5. Adults are motivated to learn because of internal factors, such as 
self-esteem, recognition, better quality of life, greater self-confidence, the 
opportunity to self-actualize, and so forth.  External factors, such as 
pressure from authority figures, salary increases, and the like, are less 
important. (p 299-300) 
After an exhaustive literature review, articles discussing the use of teaching 
techniques based on findings using any particular statistical method, including EFA were 
not found.  However, based on adult learning theory, specifically transformational 
learning, and this writer’s nursing experience with both the target group, heart failure 
patients with or without low systolic blood pressure and extensive experience teaching 
medical residents in structured programs, the following information was used to support 
the use of the andragogical approach to teaching emergency room residents to use the 
risk model to be developed.  The use of the andragogical technique is based on the results 
of the EFA conducted.  If other results were found, then it is plausible an alternate 
teaching style may be appropriate and would have been explored. 
The underlying assumptions in the andragogy model by Knowles, Holton, and 
Swanson (2005, p 294-295) are matched below to the method of learning of a risk model 
by emergency room residents.  The second and third assumptions directly relate to the 
factors found in the EFA conducted since the literature reports that patients with and 
without low systolic pressure are different.  It also important that the two common factors 
shared by patients regardless of blood pressure at presentation are directly related to 
blood pressure.  Risk models are powerful tools for assessing biomedical significance but 
the importance of how to teach and use a risk model cannot be underestimated.  The 
purpose of this study was to compare patients who presented with acute decompensated 
heart failure and to determine if patients with low systolic blood pressure share common 
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factors with patients with normal to high blood pressure at presentation. There is paucity 
in the literature based on the exclusion of patients with low systolic blood pressure in 
randomized clinical trials.  Currently, treatment of patients with low systolic blood pressure 
is approached differently, yet both groups share common factors.  Building on what 
emergency room residents may know, or determining whether there is a knowledge deficit 
is extremely important.  Unlike problem-based learning which takes the pedagogical 
approach, emergency room residents already have the training and understanding to treat 
the target group of patients. 
1. “The learner is self-directing” (Knowles, Holton, &Swanson, 2005, p. 299). 
Emergency room residents are practicing under an attending physician to be able to 
independently treat patients including those who present with acute decompensated heart 
failure with or without low systolic blood pressure.  The focus of their training is to become 
independent. 
2. “The learner enters an educational situation with a great deal of experience” 
(Knowles, Holton, &Swanson, 2005, p. 299).  Emergency room residents have not only 
completed medical school and criteria for residency matching but several other medical 
rotations including internal medicine in their training in order to practice in the emergency 
room.  However, a step-by-step process layering information on what is already known 
(present level of understanding) by the leaner o the required knowledge level is needed. 
3. “Adults are ready to learn when they perceive a need to know or do 
something in order to perform more effectively in some aspect of their lives. Their 
readiness to learn may be stimulated by helping them to assess the gaps between where 
they are now and where they want and need to be” (Knowles, Holton, &Swanson, 2005, 
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p. 299).  There is a paucity of data characterizing the patient with low systolic blood 
pressure and heart failure in the literature and thus, this was the basis of this retrospective 
study.  Clinical trials exclude patients with heart failure and low systolic blood pressure 
and these patients are often treated differently than those who were included in 
randomized clinical trials testing medication in those with normal or high blood pressure.  
However, the results of the EFA conducted indicates that patients with and without low 
systolic blood pressure share common factors.  These factors, anemia and kidney 
function also directly affect blood pressure.  If emergency room residents do not know 
that these factors are shared, then the first step would be to educate them about this 
finding.  Despite extensive education, training, and experience, the emergency physician 
will not have seen every variation of every condition that a patients presents with in the 
emergency department and they cannot be expected to have vast knowledge of every 
possibility or to have access to that knowledge readily.  Having access and time to 
analyze all of the data to compare outcomes is not expected of a clinical provider and is 
left to researchers.  That is why a risk model would be extremely important for the 
emergency room physician to access to assess patients quickly and safely prior to 
initiating, stopping or containing a treatment.  Using statistical approaches such as EFA 
can elicit surprising new associations in the clinical data that a clinical treating physician 
would not expect.  If emergency room residents do know from prior knowledge (underlying 
assumption 1), then the teacher would be adding to their knowledge base when teaching 
the residents the use of the risk model.  Expanding on Knowles’ contribution, Mezirow’s 
(1991) transformational learning theory provides for an improved, meaningful learning 
experience for the adult learner and, “…the educator must actively encourage reflective 
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discourse through which learners can examine the justification for their meaning schemes 
and perspectives as well as focusing on the new data presented” (p. 201). 
4. “Adults are motivated to learn after they experience a need in their life 
situation” (Knowles, Holton, &Swanson, 2005, p. 299).  Decisions are made quickly in the 
emergency room and thus using a tool like a risk model would enhance the emergency 
room physician’s decision making abilities.  Emergency workflow is based on expedient 
triage and treatment for either hospital admission or discharge.  One problem of 
overcrowding seen in the emergency room is that patients leave without being seen or 
fully evaluated (Chan, Killeen, Kelly, & Guss, 2005). The factors resulting from this EFA 
will be tested in a confirmatory fashion and then used to develop a risk model which can 
be used as a biomedical model for treatment of the target group. 
5. “Adults are motivated to learn because of internal factors, such as self-
esteem, recognition, better quality of life, greater self-confidence, the opportunity to self-
actualize, and so forth” (Knowles, Holton, &Swanson, 2005, p. 299).  It is vital to determine 
if the treating emergency room resident is exposed to transformational learning in order 
to incorporate new information in their current practice.  The practice of emergency 
medicine retains its own unique processes that are generally followed during the course 
of patient care and can be found in the institution’s policy and procedure guidelines.  At 
each step, barriers can increase risk and threaten patient safety.  From a physician’s 
standpoint, these may be potential medical-legal pitfalls.  Learning opportunities to 
provide the quickest, safest medical care allows emergency room physicians more 
autonomy in their practice.  Accurate detailed history taking, assessment of risk factors, 
test results and the patient’s individualized emergency room course are used to formulate 
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the medical treatment plan that can be expected by any reasonable physician and 
understood by any juror.  Reflection back to prior learning to better understand the present 
circumstance is perhaps more fundamental to adult learning then explaining established 
meaning schemes. 
Expanding on Knowles’ contribution, Mezirow’s (1991) transformational learning 
theory provides for an improved, meaningful learning experience for the adult learner and, 
“the educator must actively encourage reflective discourse through which learners can 
examine the justification for their meaning schemes and perspectives as well as focusing 
on the new data presented” (p.201).  Teaching in a learning environment that allows for 
trial and error without the risk of negative criticism from both the physician teacher and 
colleagues encourages learner participation and willingness to participate in learning 
opportunities. 
A discussion of how the brain learns is warranted at this point.  The following figure 
(Figure 12) illustrates the Triune Brain.  Tri refers to three, i.e., the reptilian (R-complex), 
paleomammalian (limbic system) and neomammalian (neocortex) brains and Une to one, 
i.e., one brain. 
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Figure 12: Triune Brain 
http://www.mini.ca/settings?ReturnUrl=http%3A%2F%2Fwww.mini.ca%2F 
The primitive, reptilian part of the brain dominates when there is perceived threat 
or under conditions of negative stress (distress as opposed to positive stress or eustress) 
and the response is reactionary without reasoning resulting in a downshifting.  There is a 
literal shift down from the higher thinking of the neocortex to the social bond of the limbic 
and to the survival of the reptilian part. Learners who perceive a threat feel helpless and 
their thinking or emotions shift to behavior characterized as reptilian.  For effective 
learning to occur, there must be a dynamic balance between the challenge of learning 
(i.e., stress) and a safe environment (Caine & Caine 1991).  Physician leaders who create 
an environment of negative feelings using ridicule or belittling by making comparisons or 
unhealthy competition when training medical residents build a defensive and acquiescent 
cohort.  Alternatively, a positive learning environment which provides for relaxed learning 
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and feelings of acceptance allows the learning to function in the neocrotex where feeling 
associated with thinking is logical, sophisticated and thinking, creativity and reasoning is 
performed.  This is especially important when introducing a new concept such as a new 
Acute Decompensated Heart Failure Risk Model.  A break in the routine or a change in 
the curriculum may evoke emotion that may be upsetting to both the teacher and learner 
(MacLean, 1978).  Teaching the use of a new Acute Decompensated Heart Failure Risk 
Model to Emergency Room Residents will be most successful if a transformative 
approach is utilized by the physician educator. 
Methods for, and approaches to, medical education and general education have 
most significant ties dating back to the Flexnor report.  The Carnegie Foundation for the 
Advancement of Teaching brought in Abraham Flexner to visit and evaluate medical 
school education in the U.S. and Canada at the turn of the 20th century.  Flexor, a teacher 
from Louisville, Kentucky attended graduate school at Harvard from 1905-1906 and the 
following year studying the university-based medical education in Germany.  In 1908, 
Flexner visited 155 medical schools in the U.S. and Canada over a 13 month period to 
write a report of his evaluation and assessment of physician training resulting in the 
closure of one third of the schools.  The main concentrations written in the Flexnor report 
are to establish an association between medical schools and universities thus eliminating 
proprietary medical schools, mandate the basic science laboratory rotation, and ensure 
a progressive medical education as seen in elementary and secondary school education 
(Duffy, 2011). Competency-based instruction is built-in the Flexnerian program since 
medical residents are adult learners who tend to be self-directed and willing to assume 
responsibility in the learning process. As a supporter of the educator John Dewey, Flexor 
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understood medical education has analogies to elementary and secondary school 
education in, “that ‘the initiative lies with the learner’ and that education involves more 
than an accumulation of facts but a method of inquiry, thinking and problem solving.” 
(Arky, 2007, p. 91). 
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APPENDIX A 
New York Heart Association (NYHA) Classification 
Functional Capacity Objective Assessment 
Class I. Patients with cardiac disease but without resulting 
limitation of physical activity. Ordinary physical activity does 
not cause undue fatigue, palpitation, dyspnea, or anginal 
pain. 
A. No objective evidence 
of cardiovascular 
disease. 
Class II. Patients with cardiac disease resulting in slight 
limitation of physical activity. They are comfortable at rest. 
Ordinary physical activity results in fatigue, palpitation, 
dyspnea, or anginal pain. 
B. Objective evidence of 
minimal cardiovascular 
disease. 
Class III. Patients with cardiac disease resulting in marked 
limitation of physical activity. They are comfortable at rest. 
Less than ordinary activity causes fatigue, palpitation, 
dyspnea, or anginal pain. 
C. Objective evidence of 
moderately severe 
cardiovascular disease. 
Class IV. Patients with cardiac disease resulting in inability 
to carry on any physical activity without discomfort. 
Symptoms of heart failure or the anginal syndrome may be 
present even at rest. If any physical activity is undertaken, 
discomfort is increased. 
D. Objective evidence of 
severe cardiovascular 
disease. 
*The Criteria Committee of the New York Heart Association. Nomenclature and Criteria 
for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, 
Brown & Co; 1994:253-256. 
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APPENDIX B 
Clinical Trial Phases 
C  
http://columbiasciencereview.com/2015/04/18/a-promising-cure-for-alzheimers-disease/ 
http://www.phrma.org/innovation/clinical-trials 
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APPENDIX C 
Henry Ford Hospital Internal Review Board (IRB) Yearly Initial IRB Approval
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APPENDIX D 
Wayne State University Human Investigation Committee (HIC) Initial IRB Approval 
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APPENDIX E 
Henry Ford Hospital Continuation Approval 
APPENDIX F 
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Wayne State University Human Investigation Committee (HIC) Continuation 
Approval
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APPENDIX G 
Collaborative Institutional Training Initiative (CITI) Certification 
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APPENDIX H 
Collaborative Institutional Training Initiative (CITI) Refresher Certification
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Collaborative Institutional Training Initiative (CITI) Refresher Certification
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APPENDIX I 
International Classification of Diseases, Ninth Revision, Clinical Modification 
 
1.  428 Heart failure 
2.  428.0 Congestive heart failure, unspecified convert 428.0 to ICD-10-CM 
3.  428.1 Left heart failure convert 428.1 to ICD-10-CM 
4.  428.2 Systolic heart failure 
5.  428.20 Systolic heart failure, unspecified convert 428.20 to ICD-10-CM 
6.  428.21 Acute systolic heart failure convert 428.21 to ICD-10-CM 
7.  428.22 Chronic systolic heart failure convert 428.22 to ICD-10-CM 
8.  428.23 Acute on chronic systolic heart failure convert 428.23 to ICD-10-CM 
9.  428.3 Diastolic heart failure 
10.  428.30 Diastolic heart failure, unspecified convert 428.30 to ICD-10-CM 
11.  428.31 Acute diastolic heart failure convert 428.31 to ICD-10-CM 
12.  428.32 Chronic diastolic heart failure convert 428.32 to ICD-10-CM 
13.  428.33 Acute on chronic diastolic heart failure convert 428.33 to ICD-10-CM 
14.  428.4 Combined systolic and diastolic heart failure 
15.  428.40 Combined systolic and diastolic heart failure, unspecified convert 428.40 
to ICD-10-CM 
16.  428.41 Acute combined systolic and diastolic heart failure convert 428.41 to 
ICD-10-CM 
17.  428.42 Chronic combined systolic and diastolic heart failure convert 428.42 to 
ICD-10-CM 
18.  428.43 Acute on chronic combined systolic and diastolic heart failure convert 
428.43 to ICD-10-CM 
19.  428.9 Heart failure, unspecified convert 428.9 to ICD-10-CM 
http://www.icd9data.com/2012/Volume1/390-459/420-429/428/ 
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Appendix J 
Epic Report Information Technology Request
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APPENDIX K 
Epic Report Information Technology Approval 
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ABSTRACT 
DEVELOPMENT OF THE ACUTE DECOMPENSATED HEART FAILURE RISK 
MODEL FOR EMERGENCY ROOM RESIDENT TRAINING 
 
by 
ZORA INJIC 
May 2016 
Advisor:  Shlomo Sawilowsky, Ph.D. 
Major:  Education Evaluation and Research 
Degree:  Doctor of Philosophy 
The purpose of this study was to characterize patients hospitalized with acute 
decompensated heart failure with and without low systolic blood pressure using 
exploratory factor analysis (EFA). Direct and surrogate measurements were measured.  
The aim was to use EFA for data reduction to elicit a parsimonious set of factors 
summarizing the relationships between variables by measuring intercorrelations of the 
clinical variables collected as part of standard care, and abstracted from electronic 
medical records. 
A better understanding of the characteristics and outcomes of the target group 
could potentially lead to individualized treatment modalities tailored to effectively and 
economically improve care.  Patients hospitalized are at a high risk for adverse outcomes 
after discharge. 
Prospectively collected new data is expensive, labor-, and time- intensive while the 
use of existing data allows a quicker, more efficient and less expensive source.  A large 
urban, academic teaching hospital was the study site.  Wayne State University Human 
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Investigation Committee and Henry Ford Internal Review expedited review approval was 
obtained. 
Eligible cases were patients hospitalized with a primary diagnosis of acute 
decompensated heart failure for the 2014 year.  Variables collected were identified based 
on review of the literature, Framingham criteria, clinical relevance, and were routinely 
availability. 
As is the case in empirical studies, determining sample size in EFA, a large sample 
size technique, is based on the minimum necessary to obtain reliable results from the 
analysis.  Guidelines or a rule of thumb by expert opinions such as Gorsuch (1983) and 
Kline (1994) include absolute numbers of at least 100 cases. 
Dimension reduction of factors via SPSS (ver 23) was conducted on all cases 
regardless of presenting systolic blood pressure (Group 1), cases with normal to high 
systolic blood pressure (Group 2) and cases with low systolic blood pressure (Group 3) 
separately, for a total of groups.  All cases were screened for entry criteria and the first 
300 chronologically dated cases were identified. 
EFA was conducted on the data abstracted from 300 electronic medical records.  
The major findings of the study were that two factors, Anemia and Kidney Function were 
seen across the three groups.  Several individual factors that affect kidney function were 
found.  Data reduction using EFA is a highly pragmatic function. Computer software 
programs such as SPSS® allow for quick and easy computations and a large number of 
variables can be directly imported from databases such as Excel®. However, EFA is a 
complex procedure with fewer absolute guidelines or rules for selecting options compared 
to other statistical approaches. The steps taken were detailed, justified by the literature 
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reviewed and alternate choices were discussed. The seven stages in factor analysis 
design as outlined by Hair et al. (2006) were employed in this analysis. 
The factors identified in each group using EFA can be tested in a future 
confirmatory factor analysis study.  Once these factors are the confirmed, an Acute 
Decompensated Heart Failure Risk Model can be developed for Emergency Room 
Resident Training within the context of evidence-based medicine. 
The pedagogical approach in medical education where instruction is provided by 
the experienced physician to the novice, namely the medical resident, is in conflict of adult 
learning theory leading to a contributing factor to the success or failure of teaching 
evidence-based medicine.  Risk models are powerful tools for assessing biomedical 
significance but the importance of how to teach and use a risk model cannot be 
underestimated.  Building on what emergency room residents may know, or determining 
whether there is a knowledge deficit is extremely important.  A step-by-step process 
layering information on what is already known (present level of understanding) by the 
leaner o the required knowledge level is needed.  The results of the EFA conducted 
indicates that patients with and without low systolic blood pressure share common factors.  
These factors, anemia and kidney function also directly affect blood pressure.  If 
emergency room residents do not know that these factors are shared, then the first step 
would be to educate them about this finding.  If emergency room residents do know from 
prior knowledge, then the teacher would be adding to their knowledge base when 
teaching the residents the use of the risk model as is described by Knowles, Holton, and 
Swanson (2005) as the first underlying assumption.  The shift to student centered learning 
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is based on adult learning theory (Spencer, 1999) and transformational learning should 
be employed. 
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